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Disclaimer 
 
This document is a general guide to appropriate practice, to be followed subject to the clinician’s judgement 
and patient’s preference in each individual case. The guidelines are designed to provide information to assist 
decision-making and are based on the best available evidence at the time of development of this publication. 
This guideline includes recommendations by clinical experts where research evidence does not currently 
exist. Wherever guidance is provided that is not directly informed by research evidence, the document will 
highlight these sections as “Consensus Statement” (CS). 
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Executive summary 
 
This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients 
being treated with Buvidal® long-acting injected buprenorphine preparations. 
 
Buvidal® is a prolonged-release formulation of buprenorphine (BPN), registered in the UK for ‘Treatment of 
opioid dependence within a framework of medical, social and psychological treatment’. Treatment is intended 
for use in adults and adolescents aged 16 years or over. Buvidal® is designed to be administered by 
subcutaneous injection once a week or once a month.  
 
Weekly Buvidal® is available in four dose strengths in prefilled syringes with a 23-gauge needle: 8 mg/0.16 mL, 
16 mg/0.32 mL, 24 mg/0.48 mL or 32 mg/0.64 mL BPN as the active ingredient.  
Monthly Buvidal® is available in three dose strengths in prefilled syringes with a 23-gauge needle: 64 mg/0.18 
mL, 96 mg/0.27 mL or 128 mg/0.36 mL BPN as the active ingredient. 
 
Framework for treatment with depot BPN products 
 
Key elements of safe and effective opioid substitution treatment (OST) include; safe and effective use of 
medicine; regular clinical reviews and monitoring; participation in psychosocial interventions; and addressing 
medical, mental health and social comorbidities. 
 
It is essential that patients are provided with accurate information and options regarding their medication and 
treatment, as part of informed decision making and consent. Once-a-week and once-a-month depot injections 
reduce the need for daily supervised and/or ‘take-away’ doses of sublingual (SL) BPN formulations. Potential 
benefits of depot BPN treatment include:  
 
• greater convenience for patients as they will not have to attend dosing sites (pharmacies, clinics) on a 
frequent basis for supervised dosing or collection 
• reduced treatment costs 
• greater medication adherence and enhanced treatment outcomes for some patients who struggle to 
attend regularly for dosing with SL BPN 
• lower risk of diversion and non-medical use of the medication, enhancing community safety.  
 
However, depot BPN formulations may not suit all patients, and some will prefer SL BPN or methadone 
treatment, and these options should be available. Buvidal® must be administered by registered health 
practitioners and must not be handled by or dispensed to patients or carers. 
 
Dosing recommendation for Buvidal®  
 
Patients treated with SL BPN formulations may be transitioned directly to Buvidal® prolonged-release injections 
starting on the day after the last daily SL treatment dose (see conversion recommendations in Table 1). 
Patients should be reviewed prior to the next scheduled dose and assessed for adverse events, withdrawal, 
cravings, substance use and the patient’s rating of dose adequacy. Individual clinical titration of doses may be 
required on subsequent doses, recognising that the dose effects of depot formulations are likely to increase 
with BPN accumulation until steady state equilibrium is achieved (usually after 4 doses). 
 
Table 1: Dose conversions between SL BPN, depot weekly Buvidal® and monthly Buvidal® doses 1 2 3 4 5 
Dose of daily sublingual 
buprenorphine 
Dose of daily 
Espranor®  
Dose of weekly 
Buvidal® 
Dose of monthly 
Buvidal® 
2-6mg 2-4 mg 8mg  
8-10mg 6-8mg 16mg 64mg 
12-16mg 10-12mg 24mg 96mg 
18-24mg 14-18mg 32mg 128mg 
 25-30% higher bioavailability for Espranor® than for sublingual Subutex® tablet  
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Commencing BPN treatment with Buvidal®.  
 
Depot BPN should be started when objective and clear signs of mild to moderate withdrawal are evident. For 
patients who have not previously been exposed to BPN a SL BPN test dose should be given prior to the 
administration of a weekly Buvidal® prolonged-release injection to confirm tolerability to BPN.  A sublingual 
BPN 4 mg dose should be administered and the patient should be observed for an hour to confirm tolerability to 
BPN. The recommended starting dose of weekly Buvidal® for patients not previously receiving BPN is 16 mg, 
with one or two additional 8 mg doses at least 1 day apart. The recommended dose for the second treatment 
week is the total dose administered during the week of initiation.  
 
A clinical decision may be made that a test dose is desirable to reduce the risk of precipitated withdrawal in 
patients who are not already receiving BPN. A validated tool such as the Clinical Opiate Withdrawal (COWS) 
scale can be used to support this assessment (e.g. COWS score of 10 or more). Clinicians should monitor 
levels of withdrawal so that the patient does not become too uncomfortable (CS). 
 
Patients may be switched from weekly to monthly dosing or from monthly to weekly dosing based on the 
recommendations in Table 1. Patients can be switched from weekly to monthly Buvidal® after 4 weeks of 
treatment. In some instances, clinicians may consider switching sooner based upon an assessment of broader 
risks and overall treatment benefit (for example retention in treatment and/or patient wishes). Patients switching 
from weekly to monthly dosing will generally experience trough levels in the first few months similar to patients 
switching from SL BPN. Patients should be monitored for increased withdrawal or craving symptoms or other 
signs of instability. Titration to higher or lower doses may be required. 
 
Flexible dosing 
 
‘Top-up’ or supplemental doses of Buvidal® may be given if the patient experiences clinical features of opioid 
withdrawal, cravings or persistent unsanctioned opioid use. Examples include; during dose titration in the early 
stages of depot treatment; following drug-drug interaction (DDI); and delayed or interrupted depot dosing due 
to unforeseen circumstances such as travel, transport problems, or other commitments.  
 
If clinically indicated, a maximum of one supplemental Buvidal® 8mg dose may be administered at an 
unscheduled visit between regular weekly and monthly doses. The maximum dose per week for patients who 
are on weekly Buvidal® treatment is 32mg with an additional 8mg dose (i.e. 40mg). The maximum dose per 
month for patients on monthly Buvidal® is 128 mg with an additional supplementary 8 mg dose (i.e. 136 mg). 
There may be circumstances where top up or supplemental doses of BPN are required but it is not possible to 
organise weekly Buvidal® 8mg doses (e.g. travel away from regular service providers). Supplemental low doses 
of SL BPN (e.g. 4mg or 8mg) may be used for a limited period until the next depot injection can be organised 
(CS). 
 
Induction from other opioids: prescription opioids and methadone 
 
To avoid precipitating symptoms of withdrawal, treatment with Buvidal® should be started when objective and 
clear signs of mild to moderate withdrawal are evident. Consideration should be given to the types of opioid 
used (that is long- or short-acting opioid), time since last opioid use and the degree of opioid dependence. For 
patients using heroin or short-acting opioids, the initial dose of Buvidal® must not be administered until at least 
6 hours after the patient last used opioids. For patients receiving methadone, the methadone dose should be 
reduced to a maximum of 30 mg/day before starting treatment with Buvidal® which should not be administered 
until at least 24 hours after the patient last received a methadone dose. Buvidal® may trigger withdrawal 
symptoms in methadone-dependent patients. 
 
Potential scenarios for discontinuing depot BPN treatment  
 
Potential scenarios for discontinuing depot BPN treatment include: withdrawing off depot BPN (with goal of 
opioid abstinence), transfers to SL BPN, transfer to methadone / other OSTs, and transfer to oral naltrexone. 
Patients who have been in treatment for long enough to achieve steady state plasma levels of depot BPN are 
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likely to have a longer time course of reduction of BPN levels and therefore longer time course of withdrawal 
symptoms than those on depot BPN treatment for shorter periods. In general, the withdrawal syndrome from 
depot BPN is expected to occur several weeks to several months after the last dose, persist for longer, and 
may be of lower severity than withdrawal from SL BPN. 
 
Wherever possible, patients should reduce depot BPN dose prior to discontinuing dosing. For patients on 
monthly Buvidal® this could involve switching to the weekly preparation before ceasing depot BPN. It is 
generally recommended to taper the depot dose to the lowest possible before discontinuing treatment. Patients 
and treatment plans should be reviewed regularly, with additional psychosocial support to maintain motivation, 
and cope with cravings, withdrawal and the risk of relapse. There may be a role for symptomatic medication to 
assist with features of opioid withdrawal, however caution should be applied when considering extended use 
(beyond a few days) of sedatives or hypnotic medications. Given the risk of relapse patients who have 
withdrawn from depot BPN should be supplied with take-home naloxone. 
 
Transfers to methadone 
 
There is currently little clinical experience and no published studies regarding transfer from depot BPN to 
methadone. Given this lack of evidence, it is suggested that patients seeking to transfer from depot BPN to 
methadone should transition via SL BPN. Once stabilised on a dose of SL BPN for at least 4 weeks then 
transition to methadone can occur however it is recommended to initiate at low doses (20-30mg daily), 
reviewing regularly and titrating accordingly (CS). 
 
Safety issues regarding use of depot products  
 
Buvidal® should not be administered to anyone hypersensitive to BPN or any of the excipients [glycerol 
dioleate, phosphatidyl choline [soybean], and N-methyl-2- pyrrolidone (in weekly Buvidal®) and ethanol 
anhydrous (in monthly Buvidal®)]. Buvidal® should not be administered to patients with severe respiratory 
insufficiency, severe hepatic impairment or acute alcoholism or delirium tremens. 
 
The features of hypersensitivity to BPN include rashes, hives, and pruritis. Most serious reported cases have 
involved bronchospasm, angioneurotic oedema, and anaphylactic shock. It should be noted that 
hypersensitivity to BPN is very rare. 
 
Adverse events  
 
Side effects of depot BPN are similar to the known safety profile of BPN administered sublingually with the 
exception of adverse events related to injection of the drug. The adverse reactions most frequently reported for 
BPN are headache, nausea, hyperhidrosis, insomnia, drug withdrawal syndrome and pain. Readers are 
referred to the Summary of Product Characteristics (SPC) for detailed information 
1 2
. 
 
DDIs are expected to be the same as for SL BPN, however the long duration of depot BPN effects may result 
in prolonged DDI.  
 
Pregnancy and breastfeeding 
 
BPN remains an option for pregnant women who have already been initiated onto BPN but pregnant women 
should not be initiated onto BPN due to potential risks of opioid withdrawal in the foetus. BPN should be used 
during pregnancy only if the potential benefit outweighs the potential risk to the foetus. Pregnant women on 
depot BPN may be transferred to SL BPN. However, there may be clinical situations where pregnant women 
may not easily transfer to SL BPN. 
 
Plasma levels of BPN seen with depot treatment are generally sustained over the weekly or monthly dosing 
interval compared to the concentrations with SL BPN which fluctuate based on the daily dosing interval. 
However it is not anticipated that this will result in significant differences in BPN levels in breastmilk. The 
developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need 
for depot BPN treatment and any potential adverse effects on the breastfed child from the drug or from the 
 
SMMGP Clinical guidelines for the use of prolonged-release buprenorphine (Buvidal®) in the treatment of opioid dependence             
7  
underlying maternal condition. Breastfeeding for mothers on BPN is encouraged, even if the mother continues 
to use drugs, except where she uses cocaine or crack cocaine, or a very high dose of benzodiazepines 6. 
Breast feeding may reduce the intensity and length of the Neonatal Abstinence Syndrome (NAS) and has been 
shown to improve outcomes. 
 
Driving, operating machinery.  
 
BPN may impair the mental or physical abilities required for the performance of potentially dangerous tasks 
such as driving a vehicle or operating machinery. BPN plasma levels accumulate during the first four doses of 
Buvidal®. Patients should be cautioned about driving or operating hazardous machinery until the prescriber and 
patient are satisfied that depot BPN does not adversely affect their ability to engage in such activities.  
 
Administration of depot products by other routes 
 
Both depot products are intended for subcutaneous administration and should never be injected 
intramuscularly, intra-dermally, intravenously or intra-arterially. For this reason, depot formulations must be 
administered by a suitable healthcare professional, and never be dispensed or supplied directly to the patient 
or carer.  
 
Special populations, treatment settings and clinical scenario 
 
The use of depot BPN products in certain patient populations and treatment settings (for example criminal 
justice, hospitals, and residential rehabilitation), and in the management of particular clinical scenarios (pain 
management, intoxicated presentations) is described in the full guidelines document. 
 
Regulatory requirements  
 
Buprenorphine is considered a controlled Class C drug under the 1971 Misuse of Drugs Act. It is subject to the 
Misuse of Drugs (Safe Custody) (Amended) Regulations 2007 detailing requirements for supply and 
possession in the UK. Buprenorphine sits in schedule 3 of the regulations. It is subject to special prescribing 
and safe custody requirements. 
 
Prescriptions can be written on FP10, for dispensing to a healthcare professional to be administered in service 
or for administration by a suitably qualified community pharmacist where a Patient Specific Directive is in place. 
Buvidal® can be ordered by a service direct from a wholesale supplier where the service is in receipt of a Home 
Office license for the purchase of controlled drugs. 
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1 Background to guideline for depot BPN 
for the treatment of opioid dependence 
 
This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients 
being treated with Buvidal® long-acting injected buprenorphine preparations. 
 
Buvidal® (developed under the name CAM2038 and manufactured by Camurus AB, and also known as 
Brixadi™ in the United States (US)) was approved in the UK in November 2018 for ‘treatment of opioid 
dependence within a framework of medical, social and psychological support’. It is intended for use in adults 
and adolescents aged 16 years or over.  
 
A National Institute for Health and Care Excellence (NICE) evidence summary in February 2019 found:                          
 
‘Buprenorphine depot injection may be an option where there is a risk of diversion of opioid substitution 
medicines or concerns about the safety of medicines stored at home. It may also be an option for people who 
have difficulties adhering to daily supervised opioid substitution medication, such as for people who are 
working or in education. Buprenorphine depot injection may have a place in treating opioid dependence in 
people in custodial settings, where the risk of diversion and time needed for supervised consumption currently 
leads to challenges in supplying supervised medicines safely. However, the higher drug acquisition cost of 
buprenorphine depot injection compared with other treatments for opioid dependence will need to be taken into 
account.’ 7 
 
This guideline has been developed for treatment using depot  BPN in any clinical setting where patients receive 
OST including primary and secondary care, third sector services, private clinical settings and secure 
environments, and assumes that clinicians are familiar and experienced in the use of SL BPN products in the 
treatment of opioid dependence. 
 
This guideline document has been informed by a synthesis of: 
 
•  published evidence for Buvidal® (CAM 2038) 
•   SPCs for Buvidal® 1 2 
•   NICE Opioid dependence: buprenorphine depot injection (Buvidal®) 7 
•  The European Medicines Agency Assessment report for Buvidal® 8 
•  expert consensus group meetings in February 2020. 
 
This is the first clinical guideline for depot BPN treatment, beyond clinical trials, to be published in the UK. It is 
to be used in conjunction with Drug misuse and dependence: UK guidelines on clinical management 6 and the 
SPCs 1 2. The authors expect that future UK national guidelines will be revised to incorporate depot BPN 
preparations. 
 
As clinical experience with depot BPN preparations is at an early stage, this guideline includes 
recommendations by clinical experts where research evidence does not currently exist. Wherever guidance is 
provided that is not directly informed by research evidence, the document will highlight these sections as 
“Consensus Statement” (CS). 
 
It is anticipated that UK and international research will be published in the near future that may change 
guidance recommended in this document. The document will be reviewed in 12 months. 
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2 Introduction to OST with depot BPN 
 
2.1 Overview of treatment model of care 
 
OST (with methadone or BPN) has been demonstrated to be a safe and effective treatment approach for 
addressing opioid dependence and provides the opportunity to engage patients with other health and 
psychosocial interventions. Key elements of safe and effective OST include; safe and effective use of 
medicine; regular clinical reviews and monitoring; participation in psychosocial interventions; and addressing 
medical, mental health and social comorbidities. 
 
The UK has hitherto been restricted to medications designed to be administered once a day (or up to alternate 
day dosing for a small proportion of patients treated with SL BPN). Risks associated with methadone and BPN 
(including diversion to others, injecting medications, and overdose risks) have resulted in a treatment model 
that is predicated on supervised dosing by an appropriate professional during the early stages of treatment, 
with take-home doses becoming available according to a risk assessment and risk mitigation strategies 6. The 
reliance on daily dosing impacts greatly upon the cost and inconvenience of treatment for patients and service 
providers, and has been cited as a barrier to engagement and retention for some patients in treatment. The 
introduction of a depot BPN formulation into the UK treatment system represents a significant development in 
the model of care. 
 
The availability of buprenorphine treatment with once-a-week and once-a-month depot injections is expected to 
be associated with several potential benefits: 
 
• Greater convenience for patients as they will not have to attend dosing sites (pharmacies, clinics) on a 
frequent basis for supervised dosing or collection of medication. In the UK, many patients in SL BPN 
treatment attend daily or several times a week for supervised dosing or collection of medication. This 
can raise difficulties, in particular in rural settings where patients often have to travel large distances to 
reach dosing sites. This will also benefit patients for whom regular attendance at pharmacies is difficult 
(e.g. due to mobility problems, work issues, or caring responsibilities), or where regular attendance at a 
community pharmacy complicates confidentiality and can be associated with stigma and discrimination 
(e.g. in a rural town with only one pharmacy). 
 
• Less risk of diversion and non–medical use of the medication, enhancing community safety. Despite a 
treatment system predicated on supervised dosing, a significant minority of patients engage in non–
medical use of BPN (injecting, diversion to others, stockpiling)9. This is of particular concern in some 
settings for example criminal justice settings, and has limited the use of BPN in those environments in 
the UK, including formulations developed to reduce the risk of diversion, such as Espranor®. 
 
• Potential for greater medication adherence and enhanced treatment outcomes for patients who struggle 
to attend regularly for dosing with SL BPN due to a range of issues including homelessness, cognitive 
impairment, domestic violence issues, child-care responsibilities, psychiatric co-morbidity, physical 
mobility problems (particularly with the UK’s ageing treatment population), or regular episodes of 
incarceration. This group of patients is also often not suitable for large amounts of take-home doses of 
BPN, and can find themselves in a cycle of missed doses, polydrug use, and deteriorating health and 
social conditions. Some patients may benefit from less frequent (e.g. monthly) dosing requirements with 
the depot product, to maintain BPN adherence and to experience greater stability. 
 
The introduction of BPN formulations is likely to have significant benefits for some patients and service 
providers. However, it may not suit all patients in OST, and some patients will prefer SL BPN or methadone  
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treatment, and these options should also be available. It is essential that patients are provided accurate 
information and options regarding their treatment as part of informed decision making and consent. 
 
2.2 Evidence of efficacy of depot BPN in the treatment of opioid dependence 
 
The efficacy and safety of Buvidal® in the treatment of opioid dependence have been established in clinical 
trials. Flexible doses of monthly Buvidal® formulations were shown to be ‘non-inferior’ to SL BPN in a double 
blind randomised control trial 10 on the primary endpoint of urine samples negative for illicit opioids (see 
appendix 1). 
  
 
SMMGP Clinical guidelines for the use of prolonged-release buprenorphine (Buvidal®) in the treatment of opioid dependence             
11  
3  Clinical pharmacology 
 
3.1  General 
 
BPN is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. As a partial 
mu-opioid agonist, the effects of BPN in individuals are dose-dependent within a limited range, above which 
increasing dosages do not produce corresponding increases in effect (ceiling-effect). Thus, for certain 
pharmacologic effects (e.g. respiratory depression and sedation), buprenorphine may exhibit an enhanced 
safety profile compared with mu-opioid receptor full agonists. The clinical relevance of buprenorphine activity at 
kappa-opioid receptors remains unclear. Whilst extended-release buprenorphine formulations (e.g. ‘low-dose’ 
7-day transdermal buprenorphine patches) have been available for the treatment of pain, the depot BPN 
formulations weekly Buvidal® and monthly Buvidal® are a new generation of extended release medium-high 
dose BPN formulations for the treatment of opioid dependence 11. 
 
3.2  Formulations 
 
Buvidal® is a depot formulation of BPN designed for administration by subcutaneous (SC) injection once a 
week or once a month. 
 
The weekly Buvidal® formulation is available in four dose strengths containing 50mg/mL BPN  as the active 
ingredient in prefilled syringes with a 23-gauge needle: 8mg (0.16mL), 16mg (0.32mL), 24mg (0.48mL) or 
32mg (0.64mL). 
 
The monthly Buvidal® formulation is available in three dose strengths containing 356mg/mL BPN as the active 
ingredient in prefilled syringes with a 23-gauge needle: 64mg (0.18mL), 96mg (0.27mL) or 128mg (0.36mL). 
 
Buvidal® depots contain the active substance BPN in delivery system compositions based on the proprietary 
FluidCrystal® injection depot technology, a lipid-based liquid. When injected into the SC tissue the FluidCrystal® 
formulation absorbs interstitial aqueous body fluid and transforms from liquid to highly viscous liquid crystal (or 
gel-like) phases in situ, which effectively encapsulate the active substance. This results in a slow and 
consistent release of BPN, which can be controlled for over a week or a month depending on the composition. 
Excipients are described in the SPCs 1 2. 
 
3.3  Overview of pharmacokinetic properties 
 
The key pharmacokinetic properties of Buvidal® are detailed in the SPC 1 2. 
 
It is important to recognise that repeated use of depot BPN formulations results in accumulation over time, and 
steady state equilibrium is achieved after four doses (weekly or monthly). The average (Cavg), peak (Cmax) 
and trough (Cmin) BPN plasma concentrations seen at steady state for SL and depot BPN formulations are 
shown in Figure 1 allowing a framework for comparing dose effects across different formulations. 
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Figure 1: Pharmacokinetic parameters – steady state 
 
         
 
 
Whilst dose-proportional increases are seen within prolonged-release weekly or monthly formulations of BPN 
products, there is nevertheless considerable variation in BPN plasma levels between individuals, and Figure 1 
should be interpreted as a guide only. 
 
Whilst laboratory receptor-binding studies are of interest in our understanding of this treatment approach, they 
do not translate into clinical practice readily, and there is no clinical role for monitoring buprenorphine plasma 
levels as part of patient care. At this time, there is an inability to routinely or meaningfully measure BPN plasma 
levels or to assess opioid receptor occupancy in clinical practice. Clinicians should focus more upon individual 
patient responses to treatment with reviews of patient experience of withdrawal, cravings and continued 
substance use.  
 
Whilst continued heroin or other opioid use may be a result of inadequate BPN dose it may also be related to 
social or other health issues. Plasma BPN levels only partially account for the clinical (pharmacodynamic) 
effects experienced by patients, such as prevention of opioid withdrawal and cravings, and blockade effects. A 
range of other factors impact upon the clinical effects of BPN and must be considered when titrating BPN 
doses to achieve desired clinical outcomes, including patient expectancy, concomitant medical (e.g. chronic 
pain, hepatic disease) and psychiatric conditions, use of other opioids and substances, drug-drug interactions, 
adverse events and genetic variation. Whilst expected plasma concentrations routinely achieved with 
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formulations can serve as a guide to the selection of BPN doses and formulation, regular clinical patient 
monitoring is required. As previously highlighted, therapeutic monitoring of BPN plasma levels in clinical 
practice is not recommended and has very limited availability in the UK. 
 
3.3.1 Absorption and onset of effects 
 
After SC injection, BPN peak plasma concentrations (Cmax) are observed approximately 24 hours after the 
weekly Buvidal® injection and 6-10 hours after the monthly Buvidal® injection. After the initial BPN peak, the 
plasma BPN concentrations decrease slowly over the dosing interval. 
 
Figure 2 illustrates the BPN plasma concentration-time profile for weekly Buvidal® injection (32mg) vs 
SL BPN (24mg/day) and monthly Buvidal® injection (128mg – labeled “CAM2038”) vs weekly Buvidal® 
injection (32mg) 1 
 
 
 
3.3.2 Metabolism 
 
The metabolism of BPN is largely the same irrespective of formulation. BPN is predominantly metabolised (N-
dealkylation) by cytochrome P450 (CYP3A4) to the active metabolite norbuprenorphine, and both parent 
molecule and metabolite then undergo glucuronidation. Subcutaneous administration of depot BPN results in 
significantly lower plasma concentrations of norbuprenorphine metabolite compared to SL BPN, due to 
avoidance of first-pass metabolism invariably seen with some oral swallowing of sublingual doses.  
. 
3.3.3 Elimination and duration of effects 
 
The slow release of BPN from the depot formulations results in extended duration of action of these products. 
The terminal plasma half-life of single doses of the depot formulations are: 
 
• weekly Buvidal®: 3 to 5 days1  
• monthly Buvidal®: 19 to 25 days 2. 
 
With repeated dosing, BPN plasma levels accumulate until steady state equilibrium is achieved typically by the 
five half-lives of dosing, and needs to be considered when adjusting doses during the first few weeks or months 
of treatment. This typically means after the fourth dose (4 weeks for weekly Buvidal® and 4 months for monthly 
Buvidal®). The clinical effects of discontinuing BPN dosing will depend upon the formulation administered (e.g. 
weekly or monthly), the dose of depot administered (longer duration with higher doses), and the duration of 
 
1 This is based on the half-life of Buvidal formulations and 90% elimination of the dose 
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treatment (whether steady state has been achieved following multiple doses). 
 
Model simulations and clinical experience indicate that BPN plasma concentrations decrease slowly over time 
following the last injection and remain for extended periods – potentially up to 12 weeks for the monthly 
Buvidal® formulation and 3 weeks for the weekly formulation. The prolonged duration of effects of these depot 
formulations may impact upon the (delayed) emergence of withdrawal symptoms, experience of adverse 
events, drug-drug interactions, and transitioning onto other opioid medications (e.g. SL BPN, methadone). It 
may also result in delayed reduction of tolerance to opioids and be protective against overdose following 
resumption of heroin or other opioid use. 
 
3.3.4 Withdrawal, cravings, opioid blockade 
 
Clinical trials indicate that Buvidal® is effective in reducing opioid withdrawal and cravings for opioid use. 
Opioid blockade is defined as the inhibition of the positive physiological and subjective effects (i.e. drug liking) 
of exogenous opioids, and is achieved through BPN by its greater affinity for mu opioid receptors than 
conventional opioids such as morphine, heroin, methadone, and oxycodone 10. The blockade of subjective 
opioid effects has been demonstrated with clinical hydromorphone challenge studies with weekly Buvidal® 
products 12. These studies are summarised in appendix 1. 
 
3.4  Side effects and safety issues 
 
3.4.1 Adverse events 
 
Side effects of depot BPN are similar to the known safety profile of BPN administered sublingually 13 14 with the 
exception of adverse events related to injection of the drug 10 .The adverse reactions most frequently reported 
for buprenorphine are headache, nausea, hyperhidrosis, insomnia, drug withdrawal syndrome and pain. 
Readers are referred to the SPCs for detailed information and appendix 2 1 2. 
 
3.4.2 Contraindications 
 
Buvidal® should not be administered to anyone hypersensitive to BPN or any of the excipients [glycerol dioleate 
phosphatidyl choline [soybean], and N-methyl-2- pyrrolidone (in weekly Buvidal®) and ethanol anhydrous (in 
monthly Buvidal®)]. Buvidal®  should not be administered to patients with severe respiratory insufficiency, 
severe hepatic impairment or acute alcoholism or delirium tremens 1 2. 
 
The features of hypersensitivity to BPN include rashes, hives, and pruritis. Most serious reported cases have 
involved bronchospasm, angioneurotic oedema, and anaphylactic shock. It should be noted that 
hypersensitivity to buprenorphine is very rare. 
 
3.5  Special Warnings 
 
3.5.1 Risk of serious harm or death with intravenous administration 
 
Care must be taken to avoid inadvertent injection of depot BPN into a blood vessel, intramuscularly or 
intradermally (into the skin). Intradermal injection may result in severe inflammation and local infection. 
Intravenous injection presents significant risk of serious harm or death as depot BPN forms a solid mass upon 
contact with body fluids which potentially could cause blood vessel injury, occlusion, or thromboembolic events. 
 
3.5.2 Risk of respiratory and central nervous system (CNS) depression 
 
BPN has been associated with life-threatening respiratory depression. Use depot BPN with caution in patients 
with significantly compromised respiratory function (e.g. chronic obstructive pulmonary disease, cor pulmonale, 
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decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression). Due to its 
extended-release, if depot BPN is discontinued as a result of compromised respiratory function, monitor 
patients for ongoing BPN effects for 3 weeks for weekly Buvidal® and, 3 months for monthly Buvidal®. The 
highest risk to patients will be when the medication is at peak dose (CS). 
 
3.5.3 Precipitation of opioid withdrawal in patients dependent on full agonist 
opioids 
 
BPN may precipitate opioid withdrawal signs and symptoms in persons who are currently physically dependent 
on full opioid agonists such as heroin, morphine, or methadone, if the first dose of BPN is initiated before the 
effects of the full opioid agonist have subsided 1 2. For patients receiving methadone, the methadone dose 
should be reduced to 30mg/day and administration of the test dose (if needed) should be at least 24 hours after 
the patient received a methadone dose. 
 
3.5.4 Managing risks from concomitant use of benzodiazepines or other CNS 
depressants 
 
Depot BPN provides higher than average sustained blood levels over a weekly or monthly period compared to 
the daily changes in BPN blood levels with SL BPN. Concomitant use of BPN with Central Nervous System 
(CNS) sedatives (e.g. alcohol, benzodiazepines, TCAs, gabapentinoids and antipsychotic medications), 
increases the risk of adverse reactions, including overdose, respiratory depression, and death. It remains 
unclear whether these risks are increased or reduced with depot BPN compared with SL BPN treatments.  
 
Options to reduce this risk include stabilisation, reduction or cessation of benzodiazepines or other CNS 
depressants (usually through a monitored and gradual taper) or decreasing the doses of other sedative 
medications to the lowest effective dose. Alternative medications and non-pharmacologic treatments for anxiety 
or insomnia should be considered. Ensure that other healthcare providers are aware of the patient’s BPN 
treatment. 
 
Patient information regarding the risks of polysubstance use (including use of prescribed sedating medication), 
cautions regarding driving or operating machinery under such conditions, and the provision of take-home 
naloxone interventions are important risk mitigation approaches. 
 
Note that additional headings under ‘special warnings and precautions for use’ in the UK summary of product 
characteristics (SPC) are: prolonged-release properties, dependence, precipitation of opioid withdrawal 
syndrome, renal impairment, acute pain management, use in children and adolescents, and class effects. For 
full details please see the SPCs 1 2. 
 
3.5.5 Hepatitis, hepatic events and liver disease  
 
Moderate or severe hepatic impairment (Child Pugh B or C) slows down hepatic metabolism of BPN, resulting 
in higher plasma levels (estimated at 1.6 greater in Child B and, 2.8 times greater Child C)15 and longer half-
lives. Furthermore, cases of cytolytic hepatitis and hepatitis with jaundice have been (rarely) observed in 
individuals using BPN. The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic 
transaminases to case reports of hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic 
encephalopathy and death. In many cases, other causes of pre-existing liver disease (e.g. viral hepatitis, use of 
other potentially hepatotoxic drugs such as alcohol) may have played a causative or contributory role. Acute 
hepatitis has been reversed on BPN cessation in some cases, but not others. 
 
The effect of hepatic impairment on the pharmacokinetics of depot BPN has not been studied. Due to the long-
acting nature of the product, adjustments to depot BPN dosages are not rapidly reflected in plasma BPN levels. 
Because BPN levels cannot be decreased rapidly, patients with moderate hepatic impairment should be 
 
SMMGP Clinical guidelines for the use of prolonged-release buprenorphine (Buvidal®) in the treatment of opioid dependence             
16  
prescribed Buvidal® with caution. Buvidal® should not be used in patients with severe hepatic impairment. 
 
An assessment of hepatic function (including liver function tests) and documentation of viral hepatitis status 
prior to treatment initiation with depot BPN is recommended 1 2. Where a patient is identified as having clinically 
relevant liver disease (more than a mild elevation of LFTs) but not severe hepatic impairment, which is a 
contraindication to Buvidal® treatment, then an extended period of treatment with SL BPN (e.g. one-to-three 
months) may be an option (CS). This allows for monitoring of liver function to ensure that BPN does not worsen 
hepatic function, and for titration of BPN dose, prior to initiating depot BPN treatment. If Buvidal® is 
administered in preference to SL BPN for a patient with moderate hepatic impairment then a weekly 
formulation would be a pragmatic choice due to its quicker washout period as compared to the monthly 
prolonged-release formulation. 
 
Monitoring of liver function may be considered for patients with mild to moderate liver disease and/or liver 
impairment after commencing treatment with depot BPN (e.g. clinical examination, liver function blood tests) 
and underlying causes, for example viral hepatitis, or alcohol use). Patients who develop moderate hepatic 
impairment while being treated with depot BPN should be monitored for signs and symptoms of precipitated 
opioid withdrawal, toxicity or overdose caused by increased levels of buprenorphine. Sedation following the 
initial dose may occur with high doses, and the patient should be warned accordingly. Termination of depot 
BPN treatment may be warranted if a patient’s hepatic function significantly deteriorates; depot BPN should be 
stopped and specialist consultation is recommended. For patients who develop severe hepatic impairment, 
Buvidal® should be stopped and the patient switched to an alternative OST. As in moderate hepatic impairment 
the patient should continue to be monitored regularly following cessation of Buvidal®. 
  
3.5.6 Use in patients at risk of arrhythmia 
 
BPN has been observed to be associated with a prolonged QTc interval in some patients. Buvidal® SPCs 
recommend that caution should be exercised when co-administering Buvidal® with other medicinal products 
that prolong the QT interval and in patients with a history of long QT syndrome or other risk factors for QT 
prolongation. There are no cautions listed in the individual SPCs for oral BPN formulations. 
 
In general, Buvidal®  should be used with caution in patients with a history of long QT syndrome, or those 
taking Class IA antiarrhythmic medications (e.g. quinidine, procainamide, disopyramide), Class III 
antiarrhythmic medications (e.g. sotalol, amiodarone, dofetilide) or other medications that prolong the QT 
interval.  Existing evidence suggests that QTc prolongation and risk of arrhythmias appears to be greater with 
methadone with a significant dose-dependent risk, and is commonly linked with other substance use, including 
alcohol, cocaine, and amphetamines. A risk-benefit decision should be made regarding opioid treatment for 
patients at risk of QT prolongation. 
 
Key differences with depot BPN are that plasma levels of BPN may be consistently sustained as compared 
with SL BPN where levels will fluctuate. For patients at risk, more intensive workup prior to and or monitoring 
whilst on depot BPN treatment may be required. For assessment and management please refer to the Drug 
misuse and dependence: UK guidelines on clinical management 6. 
 
If there are significant concerns regarding BPN effects on QT prolongation, consider initiating and maintaining 
treatment with SL BPN or weekly depot BPN treatment until further investigations have been completed, as it is 
simpler to discontinue BPN using SL daily or weekly depot formulations.  
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3.5.7 Other medical conditions 
 
Significant medical conditions that warrant caution with the use of depot BPN include: 
 
• respiratory insufficiency (e.g. chronic obstructive pulmonary disease, asthma, cor pulmonale, decreased 
respiratory reserve, hypoxia, hypercapnia, pre-existing respiratory depression or kyphoscoliosis). 
• CNS depression 
• dependence 
• hepatitis and hepatic events 
• hepatic impairment 
• renal impairment 
• QT prolongation 
• acute pain management 
• opioids may cause orthostatic hypotension 
• opioids may elevate cerebrospinal fluid pressure, which may cause seizures. Therefore, opioids should 
be used with caution in patients with head injury, intracranial lesions, other circumstances where 
cerebrospinal pressure may be increased, or history of seizure 
• opioids should be used with caution in patients with hypotension, prostatic hypertrophy or urethral 
stenosis 
• opioid-induced miosis, changes in the level of consciousness or changes in the perception of pain as a 
symptom of disease may interfere with patient evaluation or obscure the diagnosis or clinical course of 
concomitant disease 
• opioids should be used with caution in patients with myxoedema, hypothyroidism, or adrenal cortical 
insufficiency (e.g. Addison's disease) 
• opioids have been shown to increase intracholedochal pressure, and should be used with caution in 
patients with dysfunction of the biliary tract. 
For details see the SPCs for Buvidal® 1 2. Assessment and management of patients with these conditions may 
require additional monitoring, consideration of the underlying aetiology and management plans. Where BPN 
treatment is required in patients with medical conditions such as those listed above, it may be prudent to use 
sublingual BPN treatment or weekly Buvidal® until the impact of BPN has been assessed, enabling easier dose 
titration and avoiding prolonged plasma levels from monthly depot injections (that cannot be reversed). 
 
3.5.8 Driving, operating machinery 
 
BPN may impair the mental or physical abilities required for the performance of potentially dangerous tasks 
such as driving a vehicle or operating machinery. BPN plasma levels accumulate during the first four doses of 
Buvidal®. Patients should be cautioned about driving or operating hazardous machinery until the prescriber and 
patient are satisfied that depot BPN does not adversely affect their ability to engage in such activities. People 
on a stable dose may not be at higher risk, providing the dose has been stabilised over some months and they 
are not using other impairing drugs. DVLA regulations on fitness to drive should also be considered, together 
with section A7 ‘Drugs and driving’ of Drug misuse and dependence: UK guidelines on clinical management 6. 
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3.5.9 Contraception advice 
 
Women on buprenorphine should be provided with advice regarding contraception as part of routine care when 
commencing opioid treatment and on an ongoing basis during treatment (see Section A.4.2 and A.7. of Drug 
misuse and dependence: UK guidelines on clinical management 6). 
 
3.5.10 Pregnancy, breastfeeding and neonatal opioid withdrawal syndrome 
 
Drug misuse and dependence: UK guidelines on clinical management  state that BPN remains an option for 
pregnant women who have already been initiated onto BPN with informed consent, but that pregnant women 
should not be initiated onto BPN due to potential risks of opioid withdrawal in the foetus 6. Buprenorphine 
should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus 1 2. BPN 
and methadone treatment, provided with adequate antenatal care, are associated with reduced maternal heroin 
use, reduced fetal death, increased neonatal birth weight and decreased premature delivery 16 17.  
 
There is a lack of research data on the safety and effectiveness of depot BPN formulations in pregnancy and 
breastfeeding. While BPN is the principal component of depot BPN, two principal differences exist compared to 
SL BPN: 
 
• higher than average sustained maternal blood levels of BPN than typically seen with SL BPN treatment 
• excipients in monthly Buvidal®. 
 
The individual risk and benefits of continuing any medication, should be considered during pregnancy. 
Pregnant women on depot BPN may be transferred to SL BPN. However, there may be clinical situations 
where pregnant women may not easily transfer to SL BPN (e.g. lack of access to daily sublingual treatment 
dosing) or it may be assessed that a pregnant woman is more likely to remain stable on depot BPN rather than 
transferring to sublingual treatment (i.e. the risks of transfer to sublingual treatment may outweigh the expected 
benefits). 
 
N-methyl-2-pyrrolidone (NMP) is an excipient in monthly Buvidal®. The levels of NMP in monthly Buvidal® are 
less than the threshold for listing in this schedule (i.e. less than 25% of the product). 
 
Whilst the mutagenic potential of NMP is weak, there is preclinical evidence of toxicity of NMP in rats and other 
animals, including decrease in foetal weight. A dose response effect in preclinical studies is noted, with 
adverse effects not being reported at lower NMP levels. In animals models the no observed adverse effect 
level was 160 to 237 mg/kg body weight, depending on route and species18. 
 
There is a lack of human data on exposure to NMP during pregnancy. There is a single case report of NMP 
exposure during pregnancy in a laboratory technician. The technician had repeated daily inhalation exposure to 
NMP from early pregnancy with direct dermal contact through a solvent spill at week 16. At week 20 
intrauterine growth restriction was noted. At week 31 the technician delivered a stillborn baby. It is not possible 
to establish a causal relationship of NMP exposure during pregnancy and the stillbirth in this case 19 20 21. 
 
Buvidal® has been approved for use in pregnancy by the European Commission where benefits outweigh the 
risks. The use of weekly or monthly formulations will be based upon individual clinical decision-making, which 
should include patient information and involvement 1 2. 
 
3.5.11 Neonatal withdrawal 
 
NAS is an expected and, potentially life-threatening outcome (if not screened for, or treated) of prolonged 
opioid exposure during pregnancy. Advise pregnant women receiving opioid treatment with depot BPN of the 
risk of NAS and ensure that appropriate treatment will be available as the onset and duration of neonatal 
withdrawal may be longer (e.g. 24 to 48 hours after expected onset with SL BPN). 
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Table 2: List of Depot BPN excipients 
 
 
soy phosphatidyl choline [soybean] Yes Yes  
glyceryl dioleate Yes Yes  
anhydrous alcohol <100mg   
N-Methylpyrrolidone  57-114mg  
 
While there is no further neonatal BPN exposure following delivery, foetal BPN exposure up until delivery may 
be higher than seen with SL BPN due to the different pharmacokinetic profile of depot BPN. Liaison with 
neonatologists / specialist pediatricians should occur regarding screening and treatment for NAS for neonates 
exposed to depot buprenorphine during pregnancy. It may be appropriate for clinicians to monitor neonates for 
a longer period than seen with SL BPN exposure, due to the different formulations. 
 
3.5.12 Breastfeeding 
 
Breastfeeding whilst being prescribed Buvidal® is listed as a caution in the SPCs 1 2. Plasma levels of BPN 
seen with depot treatment are generally sustained over the weekly or monthly dosing interval with depot 
compared to the concentrations with SL BPN which fluctuate based on the daily dosing interval. However it is 
not anticipated that this will result in significantly higher BPN levels in breastmilk. While there is not a 
substantial literature regarding BPN exposure in infants due to breastfeeding 22  the developmental and health 
benefits of breastfeeding should be considered along with the mother’s clinical need for depot BPN treatment 
and any potential adverse effects on the breastfed child from the drug or from the underlying maternal 
condition. Breastfeeding for mothers on BPN is encouraged, even if the mother continues to use drugs, except 
where she uses cocaine or crack cocaine, or a very high dose of benzodiazepines 6. Breast feeding may 
reduce the intensity and length of NAS and has been shown to improve outcomes. 
 
3.5.13 Drug–drug interactions (DDIs) 
 
A number of potentially clinically relevant DDIs exist with BPN 1 2. The SPCs for Buvidal® indicate: 
 
• interactions with other opioids (precipitated withdrawal, blockade effects) 
• interactions that increase the risk of overdose, as occurs with alcohol, other opioid drugs, 
benzodiazepines, tricyclics antidepressants, sedating antipsychotics and antihistamines) or through 
reductions in hepatic metabolism (Cytochrome P450 interactions) resulting in increased BPN plasma 
levels. 
 
Many of these DDIs are difficult to predict in advance, and generally require clinical monitoring and dose 
adjustment. However, the prolonged duration of effects of the depot BPN formulations makes sudden cessation 
of BPN and/or titration of BPN doses more difficult than when using SL BPN. More stable BPN plasma 
concentrations experienced with depot formulations may make dosing of other medication easier, particularly 
given the lack of first pass/ hepatic metabolism with Buvidal® vs SL buprenorphine. If there are significant 
concerns regarding the clinical impact of DDIs, a period of treatment with SL BPN or switching to an alternative 
OST is recommended. 
 
A detailed list of BPN interactions is available in the Drug misuse and dependence: UK guidelines on clinical 
management  (appendix A5) 6 and the SPCs for Buvidal® 1 2. For a list of DDI see appendix 3. 
  
Excipient Weekly Buvidal® Monthly Buvidal®
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4  Providing treatment with depot BPN 
 
4.1 Selecting treatment options 
 
Opioid dependence is rarely an isolated problem and often co-exists with other harmful patterns of substance 
use (e.g. cocaine often as crack, alcohol, benzodiazepines, cannabis, tobacco), and other medical, psychiatric 
and social problems. Addressing these issues involves a coordinated treatment approach with other health and 
social service providers over an extended period. 
 
OST has over many years been demonstrated to be a safe and effective treatment for addressing opioid 
dependence and provides the opportunity to engage patients with other health and psychosocial interventions. 
The key elements of OST are: 
 
• safe and effective use of medicine 
• regular clinical reviews and monitoring 
• participation in psychosocial interventions 
• addressing medical, psychiatric and social comorbidities. 
 
Drug misuse and dependence: UK guidelines on clinical management 6 state that methadone and 
buprenorphine are both effective medicines for maintenance treatment for heroin dependence, particularly 
when taken within the optimal dose range and that currently, there remains insufficient evidence to justify 
recommending one drug over the other. Furthermore, they state dose induction should aim carefully and as 
soon as possible for a stable dose of opioid that avoids both intoxication and withdrawal and a key goal of OST 
is to provide a dose that leads to complete cessation of heroin (or other illicit opioid) use. They refer to the fact 
that there is a very substantial evidence base supporting use of either of these drugs and it is appropriate for 
clinicians to discuss these complex issues with patients in obtaining informed consent for their treatment. This 
advice would apply equally when depot BPN is being considered as a treatment option. 
 
Conventional OST with methadone and SL BPN treatment usually involves frequent initial attendance for 
titration and daily supervised dispensing from a pharmacy providing the opportunity to schedule regular clinical 
reviews, medical appointments and psychosocial interventions (e.g. counselling) and this has been a well-
established treatment model in the UK for many years. However, treatment with depot BPN formulations 
potentially challenges the way in which the traditional components of OST services are coordinated and 
structured. 
 
The less frequent dosing with depot BPN formulations may require a different approach to structuring clinical 
reviews, psychosocial interventions and treatment care planning. Despite the reduced frequency of medication 
administration, it should be emphasised that safe and effective OST is more than the provision of medication, 
and that regular reviews, treatment planning, and psychosocial interventions are equally important elements of 
OST. 
 
It is possible to commence OST with weekly or monthly BPN formulations. Even though monthly BPN 
formulations are intended for 4 weekly injection intervals, clinicians may aim to schedule more frequent clinical 
reviews for patients initiating OST or during periods of clinical instability, during which assessment, care 
planning activities and psychosocial interventions can be scheduled. These issues should be discussed with 
individual patients when considering the choice of depot versus SL BPN treatment, and when developing 
treatment plans with patients.  
 
Depot BPN treatment is indicated for treatment of opioid dependence within a framework of medical, social and 
psychological support. In this context medical support may be provided by a medical practitioner (general 
practitioner, addiction medicine specialist, addiction psychiatrist or other medical practitioner) in conjunction 
with other clinical staff (e.g. nursing staff) providing depot medication injections. 
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Social and psychological support may be provided by medical, nursing and/or other staff (including drug and 
alcohol workers, pharmacists, psychologists and other disciplines) depending on patient needs and the 
resources available. 
 
4.2 Assessment and treatment planning  
 
A comprehensive assessment is an essential component of safe and effective treatment, and aims to identify 
the pattern of substance use, key medical, psychiatric and social complications, and examine patient treatment 
goals and preferences. It may take several appointments to complete the assessment. Details regarding 
assessing patients for OST are described in Drug misuse and dependence UK guidelines on clinical 
management 6. 
 
Treatment planning needs to involve the patient, taking into account their preferences and risks such as risks of 
diversion, accidental ingestion by children or others, and case complexity. It also often involves coordination 
across multiple health and welfare providers. A treatment care plan that addresses the patient’s substance use, 
physical and mental health and social issues should be developed, documented and be made available to the 
patient.  
 
Informed consent is important in this area of healthcare. Patients should understand the implications of 
different treatment options, including potential risks and benefits, side effects, and other commitments. Use of 
depot BPN formulations has some additional factors compared to oral methadone or SL BPN to be taken into 
account given the long-lasting nature of the medication and its opioid blockade effect. This may have 
implications for instance should acute pain relief be required. Patients should be provided with written 
information, and opportunities to ask questions regarding treatment options. Alternative communication 
methods may be required for patients with cognitive impairment, language and cultural factors. 
 
4.3 Patient and clinician factors in choosing depot BPN compared with other OST 
options 
 
There can be little doubt given the research evidence and long-established clinical experience that both 
methadone and BPN are safe and effective in the treatment of opioid dependence 6 23. Key factors in choosing 
between methadone and BPN medications are described in Drug misuse and dependence: UK guidelines on 
clinical management 6. These include patient factors such as prior experience with medications, adverse 
events, drug interactions, overdose risks, and in some cases logistic factors such as access to supervised 
dispensing and physical disabilities, where more flexible dosing options may be preferable. 
 
Where a decision is made in conjunction with the patient that BPN would be the most appropriate medication 
there is minimal research evidence to guide decisions regarding the choice between the depot BPN 
formulations (weekly or monthly Buvidal®) and SL BPN treatment, and individual patient and clinician factors 
need to be considered.  
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5. Guideline regarding dosing regimens  
with depot BPN 
 
5.1  Transitioning from SL BPN treatment to depot BPN  
 
Patients treated with SL BPN formulations may be transitioned directly to Buvidal® prolonged-release injections 
starting on the day after the last daily SL treatment dose (see conversion recommendations in Table 1). 
Individual clinical titration of doses may be required on subsequent doses, recognising that the dose effects of 
the depot formulations are likely to increase with BPN accumulation until steady state equilibrium is achieved 
(usually after 4 doses). 
 
Factors that may lead to the clinician and patient choosing weekly over monthly treatment may include: desire 
for more frequent clinical review or concomitant use of benzodiazepines, alcohol or other sedatives or if the 
patient presents with mild to moderate hepatic impairment. 
 
Table 1: Dose conversions between SL BPN, depot weekly Buvidal® and monthly Buvidal® doses 1 2 3 4 5 
Dose of daily sublingual 
buprenorphine 
Dose of daily 
Espranor®  
Dose of weekly 
Buvidal® 
Dose of monthly 
Buvidal® 
2-6mg 2-4 mg 8mg  
8-10mg 6-8mg 16mg 64mg 
12-16mg 10-12mg 24mg 96mg 
18-24mg 14-18mg 32mg 128mg 
 
 25-30% higher bioavailability for Espranor® than for sublingual Subutex® tablet  
 
NB Different BPN products have different maximum doses. 
 
5.2 Initiating directly to Buvidal®  
 
Depot BPN should be started when objective and clear signs of mild to moderate withdrawal are evident. A 
validated tool such COWS scale can be used to support this assessment (e.g. COWS score of 10 or more). 
Clinicians should monitor levels of withdrawal so that the patient does not become too uncomfortable (CS). 
For patients who have not previously been exposed to BPN a SL BPN test dose should be given prior to the 
administration of a weekly Buvidal® prolonged-release injection to confirm tolerability to BPN. The 
recommended starting dose of Buvidal® for patients not previously receiving BPN is 16 mg, with one or two 
additional 8 mg doses at least 1 day apart. The recommended dose for the second treatment week is the total 
dose administered during the week of initiation. A clinical decision may be made that a test dose is desirable to 
reduce the risk of precipitated withdrawal in patients who are not already receiving BPN (CS).  
 
5.3 Titrating doses of Buvidal®  
 
Patients transferred directly to monthly Buvidal® can usually continue on the conversion dose without 
experiencing cravings, withdrawal symptoms or reporting significant heroin or other non-prescribed opioid use. 
Four doses are required to achieve steady-state plasma levels. 
 
For patients initiated onto weekly Buvidal® in week 1, the recommended dose for the second treatment week is 
the total dose administered during the week of initiation. Treatment with monthly Buvidal® can be started in 
accordance with the dose conversion information in Table 1 once patients have been stabilised on weekly 
treatment. 
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5.4 Key principles in titrating depot BPN doses – adjusting dose and frequency of 
doses (CS) 
 
In general, doses should be maintained if: 
 
• the patient is achieving key treatment outcomes, such as no unsanctioned use of opioids, and no 
clinically significant opioid withdrawal or cravings 
• there are no clinically significant dose-related adverse events related to BPN (e.g. sedation or lethargy, 
persistent headaches, nausea) 
• the patient is satisfied with their current dose, and is requesting the dose be maintained. 
 
Doses should generally be reduced under the following conditions: 
 
• the patient reports BPN dose-related adverse events (e.g. sedation or lethargy, persistent headaches, 
nausea, elevated liver function tests) 
• the patient is seeking to reduce the dose in an attempt to ultimately withdraw from OST 
• the patient is reporting the dose is too high and/or is seeking a dose reduction, and there are no 
significant concerns regarding deterioration in clinical condition (e.g. substance use, physical or mental 
health symptoms) that may arise with a dose reduction 
• the patient is using other non-opioid CNS depressants which may increase their risk of opioid overdose. 
 
Dose should generally be increased under the following conditions: 
 
• the patient is not achieving desired treatment goals (e.g. persistent unsanctioned opioid use, opioid 
withdrawal symptoms or cravings) 
• the patient does not report dose-related adverse events related to BPN (e.g. sedation or lethargy, 
persistent headaches, constipation, nausea, elevated liver function tests) 
• the patient reports their dose is too low and they would like a dose increase, and there are no significant 
clinical safety concerns. 
 
The maximum dose per week for patients on weekly Buvidal® is 32 mg with an additional supplementary 8 mg 
dose (i.e. 40 mg). The maximum dose per month for patients on monthly Buvidal® is 128 mg with an additional 
supplementary 8 mg dose (i.e. 136 mg). 
 
5.5 Switching between weekly and monthly Buvidal® (CS) 
 
Patients may be switched from weekly to monthly dosing or from monthly to weekly dosing based on the 
recommendations in Table 1 (section 5.1). The SPCs recommend that patients can be switched from weekly to 
monthly Buvidal® after 4 weeks of treatment. In some instances, clinicians may consider switching sooner 
based upon an assessment of broader risks and overall treatment benefit (for example retention in treatment 
and/or patient wishes). Titration to higher or lower doses may be required. Patients switching from weekly to 
monthly dosing will generally experience trough levels in the first few months similar to patients switching from 
SL BPN. Patients should be monitored for increased withdrawal or craving symptoms or other signs of 
instability.  
 
Titration of Buvidal® may be desirable if patients present with significant opioid withdrawal during the first three 
to four doses of Buvidal® whilst steady state plasma levels are being reached. Buvidal® should be administered 
weekly or monthly according to individual patient need and clinical judgement and at doses established after 
initiation or switching.  
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5.6 Buvidal® flexible dosing schedules and supplemental BPN dosing (CS) 
 
Top-up or supplemental doses of Buvidal® may be given if the patient experiences clinical features of opioid 
withdrawal, cravings or persistent unsanctioned opioid use. In general, treatment with depot BPN should not 
routinely require additional or supplemental BPN dosing. Wherever possible, depot doses should be adjusted 
to ensure that patients are effectively and safely treated. However, there may be instances where 
supplementary doses are required. Examples include: 
 
• during dose titration in the early stages of depot treatment. For example, depot BPN doses are adjusted 
according to the patient’s prior dose, however, these transitional doses are a guide only, and 
subsequent dose adjustment may be required. Supplemental BPN doses may enable the patient to be 
held over until their next scheduled depot dose. 
• following drug-drug interaction – the commencement of another medication that induces hepatic 
metabolism of BPN (e.g. CYP 3A4 inducer such as carbamazepine) may cause BPN plasma levels to 
be reduced – resulting in features of opioid withdrawal, cravings or unsanctioned drug use. 
• delayed or interrupted depot dosing. Patients may miss their routine dose of depot BPN due to 
unforeseen circumstances, such as travel, transport problems, or other commitments. In some cases, a 
dose of depot BPN can be organised. However, in some cases patients may not be able to access their 
routine depot dose on time and interim period of treatment with SL BPN may be appropriate, given it is 
more widely available in a range of community settings than depot products. 
 
If clinically indicated, a maximum of one supplemental Buvidal® 8mg dose may be administered at an 
unscheduled visit between regular weekly and monthly doses. The maximum dose per week for patients who 
are on weekly Buvidal® treatment is 32mg with an additional 8mg dose (i.e. 40mg). The maximum dose per 
month for patients on monthly Buvidal® is 128 mg with an additional supplementary 8 mg dose (i.e. 136 mg). 
There may be circumstances where supplemental doses of BPN are required but weekly Buvidal® 8mg doses 
are not possible to administer (e.g. travel away from regular service providers). Supplemental low doses of SL 
BPN (e.g. 4mg or 8mg) may be used for a limited period of time until the next depot injection can be arranged 
(CS). 
 
Whilst doses will be routinely scheduled to occur every 7 or 28 days, it is recognised that some flexibility is 
required to accommodate missed appointments, travel, public holidays, appointment availability etc. To avoid 
missed doses, the monthly dose may be administered up to 1 week before or after the monthly time point 
(weeks 3-5). The weekly dose may be administered up to 2 days before or after the weekly time point (days 5-
9).  
 
It should be emphasised that patients should not be maintained for more than 14 days on SL BPN treatment in 
addition to depot BPN doses. Adjustment of the next depot BPN dose is recommended. If patients persistently 
describe their depot BPN dose is not sufficient despite being on the maximum possible dose (e.g. monthly 
Buvidal® 128mg) then consider discontinuing depot treatment and resuming an alternative OST. 
 
5.7 Outside Summary of Product Characteristics (CS) 
 
If a dose is missed, the next dose should be administered as soon as practically possible. If more than eight 
weeks between monthly Buvidal® has elapsed, or two weeks between weekly Buvidal® has elapsed, re-
induction may be required, with individual clinical titration (CS). 
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* For patients using heroin or short-acting opioids, the initial dose of Buvidal should not be administered until at least 6 
hours after patient last used opioids. For patients receiving methadone, the dose should be reduced to maximum of 
30mg/day and Buvidal should not be administered until at least 24 hours after last methadone dose. 
 
 
Dosing with Buvidal® 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient using 
heroin, methadone 
or other non-BPN 
opioids 
 
SL BPN 4mg test 
dose to confirm 
tolerability  
 
Patient already 
receiving SL BPN 
Initiation of treatment 
with Buvidal® 
Recommended 
starting dose, weekly 
Buvidal® 16mg,  
with 1 or 2 additional 
8mg doses at least 1 
day apart. 
Recommended dose 
for second treatment 
week is total dose 
administered during 
week of initiation 
May be transferred 
directly to weekly or 
monthly Buvidal®, 
starting on the day 
after the last daily SL 
BPN dose, in 
accordance with dose 
conversion table 
For patients not 
previously exposed  
to BPN 
Clinical review. 
Adjust frequency and dose. 
Consider: 
1. Opioid and other 
drug/ alcohol use 
2. Cravings and 
withdrawals 
3. Adverse events / DDI 
4. Patient’s views 
 
Weekly Buvidal® Monthly Buvidal® 
Dose conversion table 
Dose of daily 
sublingual 
buprenorphine 
Dose of 
daily 
Espranor® 
Dose of 
weekly 
Buvidal® 
Dose of 
monthly 
Buvidal® 
2-6mg 2-4 mg 8mg  
8-10mg 6-8mg 16mg 64mg 
12-16mg 10-12mg 24mg 96mg 
18-24mg 14-18mg 32mg 128mg 
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5.8 Induction from other opioids: prescription opioids and methadone 
 
To avoid precipitating symptoms of withdrawal, treatment with Buvidal® should be started when objective and 
clear signs of mild to moderate withdrawal are evident. Consideration should be given to the types of opioid 
used (that is long- or short-acting opioid), time since last opioid use and the degree of opioid dependence. 
• For patients using heroin or short-acting opioids, the initial dose of Buvidal® must not be administered 
until at least 6 hours after the patient last used opioids. 
• For patients receiving methadone, the methadone dose should be reduced to a maximum of 30 mg/day 
before starting treatment with Buvidal® which should not be administered until at least 24 hours after the 
patient last received a methadone dose. Buvidal® may trigger withdrawal symptoms in methadone-
dependent patients. 
 
5.9 Administering Buvidal® injections 
 
Buvidal® should be injected slowly, into the subcutaneous tissue of the buttock, thigh, abdomen, or upper arm. 
Each area can have multiple injection sites. Injection sites should be rotated for both weekly and monthly 
injections. A minimum of 8 weeks should be left before re-injecting a previously used injection site with the 
weekly dose. There is no clinical data supporting reinjection of the monthly dose into the same site. This is 
unlikely to be a safety concern. The decision to reinject at the same site should also be guided by the attending 
healthcare professional’s clinical judgement.  
 
The administered dose should be as a single injection and not divided. The dose must not be administered 
intravascularly (intravenously), intramuscularly or intradermally (into the skin). Injections on the waistline or 
within 5 cm of the naval should be avoided. The angle of injection will depend on the amount of subcutaneous 
tissue however Buvidal® should usually be administered at 90 degrees. For detailed instructions see appendix 
4 and refer to weekly Buvidal® and monthly Buvidal® SPCs 1 2. 
 
5.10 Specific issues of delivering OST with depot BPN 
 
5.10.1 Intoxicated presentations 
 
Patients presenting intoxicated at the time of dose administration should be assessed to identify any safety 
concerns regarding dosing. Peak plasma and clinical effects occur 24 hours after weekly Buvidal®, and at 6-10 
hours for monthly Buvidal®  and hence there is usually little clinical indication to withhold a depot injection due 
to a patient presenting intoxicated, in contrast to intoxicated presentations for SL BPN or methadone dosing, 
where peak medication effects are likely to occur whilst the patient is still intoxicated. However, patients should 
be assessed as having capacity to provide informed consent to their usual dose, and to understand warnings 
regarding risks of sedation and overdose from polysubstance use. If there are concerns that the patient is very 
intoxicated and unable to understand or follow instructions, the administration of the dose may be deferred and 
rescheduled. Acute alcoholism or delirium tremens are contraindications. 
 
5.10.2 Transfer of care 
 
Particular attention is required when communicating with other healthcare providers regarding transfer of care 
for patients treated with depot BPN. Many healthcare providers may be unfamiliar with Buvidal® formulations, 
and its prolonged dosing intervals.  
 
When transferring care or providing clinical handover to other healthcare providers, ensure the following is 
communicated clearly: 
 
• details of service providers prescribing and administering depot BPN injections  
• previous injection sites (in order to avoid injecting into same site) 
 
SMMGP Clinical guidelines for the use of prolonged-release buprenorphine (Buvidal®) in the treatment of opioid dependence             
27  
• dose and date of recent depot BPNs ensuring details of last dose administered are included 
• the formulation of depot BPN that was administered and the dose (in mg) 
• scheduled next dose of depot BPN (formulation, date, dose strength and route of administration) 
• any adverse events, risks or concerns regarding depot BPN treatment.  
 
As depot BPN treatment is new, untrained service providers may be unfamiliar with the treatment model or 
doses used. Providers transferring care should ensure that differences in the doses, frequency of 
administration and dispensing conditions are understood by the new provider. 
 
As depot BPN medication may not be easily administered during a brief inpatient hospital admission, it is 
possible that it may be erroneously omitted from hospital discharge summaries and medication reconciliation 
procedures. Treatment providers should endeavour to ensure that BPN treatment is accurately documented in 
transfer of care documentation and related clinical handover activities. Providers may consider the 
development of a template to support the safe transfer of care for the patient and a Standard Operating 
Procedure (SOP) outlining the process. 
 
5.11 Prescription writing 
 
Prescribers must ensure that all prescriptions for depot BPN are legally written, and compliant with the Misuse 
of Drug Regulations 2012. See Appendix A4 of Drug misuse and dependence: UK guidelines on clinical 
management (2017) for further details 6. 
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6  Discontinuing depot BPN treatment 
 
6.1 Potential scenarios for discontinuing depot BPN treatment  
 
Potential scenarios for discontinuing depot BPN treatment include: 
 
• withdrawing off depot BPN (with goal of opioid abstinence) 
• transfers to SL BPN 
• transfer to methadone / other OST 
• transfer to oral naltrexone. 
 
6.2 Withdrawing off depot BPN (with goal of opioid abstinence) 
 
Many patients in OST are keen to achieve not only abstinence from illicit drugs but also to discontinue opioid 
treatment and withdraw from all opioids. Drug misuse and dependence: UK guidelines on clinical management 
6 state that in dependent opioid users, detoxification is usually a clearly defined process, supporting safe and 
effective discontinuation of opioids while minimising withdrawals. The process varies in duration from person to 
person, usually lasting about 28 days as an inpatient or up to 12 weeks as an outpatient. This reflects the main 
evidence base on detoxification, which informs good practice. Slower detoxification often does occur and is 
supported by clinicians but has a limited evidence base.  
 
The assessment process can establish whether a patient is suitable for detoxification. It should be remembered 
that detoxification alone is rarely successful especially at the first attempt. Patients who do not successfully 
detoxify should be offered seamless access back into maintenance or other treatment. The following factors 
can guide the clinician’s and patient’s opinions about whether the patient is suitable for detoxification:  
 
• the patient is fully committed to and informed about the process  
• the patient is fully aware of the high risk of relapse  
• the patient is either in a stable and supportive social situation or able to go into one following 
detoxification  
• plans for continuing support and treatment are in place 
• there is clear evidence that coerced detoxification against a patient’s will is likely to lead to relapse and 
increased risks of harm such as overdose and blood-borne viruses.  
 
There is currently very little experience and no studies examining withdrawal from depot BPN treatment. The 
withdrawal time course and severity has not been characterised for depot BPN products.  
The onset, peak and duration of withdrawal symptoms may well be variable between patients, and is likely to 
be influenced by the duration of previous dosing of depot BPN. In general, the withdrawal syndrome from depot 
BPN is expected to occur several weeks to several months after the last dose, persist for longer, and may be of 
lower severity than withdrawal from SL BPN. 
 
Patients who have been in treatment for long enough to achieve steady state plasma levels of depot BPN are 
likely to have a longer time course of reduction of BPN levels and therefore longer time course of withdrawal 
symptoms than those on depot BPN treatment for shorter periods.  
 
Wherever possible, patients should reduce depot BPN dose prior to discontinuing dosing. For patients on 
monthly Buvidal® this could involve switching to the weekly preparation before ceasing depot BPN. It is 
generally recommended to taper the depot dose to the lowest possible before discontinuing treatment. 
 
As in attempts to withdraw from other forms of OST, patients and treatment plans should be reviewed regularly, 
with additional psychosocial supports to maintain motivation, and cope with cravings, withdrawal and the risk of 
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relapse. There may be a role for symptomatic medication to assist with features of opioid withdrawal, however 
caution should be used in using extended use (beyond a few days) of sedatives or hypnotic medications. Given 
the risks of relapse, patients who have withdrawn from depot BPN should be supplied with take-home 
naloxone. 
 
6.3 Transfers to SL BPN (CS) 
 
Given the variable excretion and clinical effects of depot BPN products there can be considerable individual 
variation in when the clinical effects of prior depot BPN treatment subside. This will be affected by prior depot 
dose (generally longer effects with higher doses), duration (generally longer effects with long-term depot 
treatment), variation in hepatic function, age, and the patient’s sensitivity to withdrawal symptoms, cravings and 
other stressors. 
 
Initiate SL BPN dosing at the time of the next scheduled injection (e.g. 5-9 days after weekly Buvidal® and 3-5 
weeks after last monthly Buvidal® injections). Dose conversion tables should be used to guide the initial SL 
BPN dose, with frequent clinical reviews in order to titrate the SL dose over subsequent days bearing in mind 
the variation in maximum doses for the various SL BPN products. 
 
Table 1: Dose conversions between SL BPN, depot weekly Buvidal® and monthly Buvidal® doses 1 2 3 4 5 
Dose of daily sublingual 
buprenorphine 
Dose of daily 
Espranor®  
Dose of weekly 
Buvidal® 
Dose of monthly 
Buvidal® 
2-6mg 2-4 mg 8mg  
8-10mg 6-8mg 16mg 64mg 
12-16mg 10-12mg 24mg 96mg 
18-24mg 14-18mg 32mg 128mg 
 25-30% higher bioavailability for Espranor® than for sublingual Subutex® tablet  
 
NB Different BPN products have different maximum doses. 
 
It should be emphasised that there remains a relative lack of experience in transferring patients from depot to 
SL BPN and faster response times, or higher or lower doses than those suggested above may be required. 
Patients should be reviewed regularly, and doses titrated according to clinical need, and clinicians should 
document the rational for their decision-making. 
 
6.4 Transfer to methadone or other opioid analgesics (CS) 
 
There is currently little clinical experience and no published studies regarding transfer from depot BPN to 
methadone. Given this lack of evidence, it is suggested that patients seeking to transfer from depot BPN to 
methadone should transition via SL BPN. Once stabilised on a dose of SL BPN for at least 4 weeks then 
transition to methadone can occur. However, it is recommended to initiate at low doses (20-30mg daily), 
reviewing regularly and titrating accordingly. 
 
If a patient has to discontinue all BPN treatment abruptly (e.g. due to a severe adverse event, or patient 
unwillingness to continue any BPN treatment), transition to methadone can be considered. The general 
principle is to commence low dose methadone (e.g. 20mg oral daily doses) at the time of the next proposed 
depot dose, regularly monitor the patient (at least weekly), and carefully increase the dose (by no more than 5-
10mg increments after clinical reviews until the methadone dose and patient have stabilised, recognising that 
residual BPN from depot BPN doses may be present for up to 4-6 months after long term treatment with 
Buvidal®.  
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6.5 Transfer to oral naltrexone (CS) 
 
Following cessation of depot BPN, transfer to oral naltrexone is feasible after BPN effects have subsided, 
typically 2-4 weeks after weekly depot BPN 4 to 12 weeks after the last dose of monthly depot BPN. However 
the risk of precipitated withdrawal under these circumstances is considerable, and transfer should generally be 
undertaken in an inpatient setting or under close observation, following a urine drug test negative for opioids, 
and ideally a negative naloxone challenge. A test dose of 25mg should then be given on day 1 and then if no 
precipitated withdrawal or adverse reactions are experienced a maintenance dose of 50mg daily should be 
prescribed in line with current UK practice. Given that this is likely to be used in a very small number of 
patients, consultation with a specialist is recommended if there are any concerns. 
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7 Clinical conditions 
 
7.1 Overdose 
 
Whilst BPN on its own is rarely associated with overdose in dependent opioid users, overdose can occur in the 
context of polydrug use, specifically the use of other sedatives such as alcohol and benzodiazepines. Under 
such circumstances, emergency treatment is required with supportive care (oxygen therapy, assisted breathing 
and recovery position) and the use of naloxone. Whilst laboratory studies (animal and receptor binding studies) 
suggest that very high doses of naloxone (e.g. 10mg IM/IV) are required to reverse the effects of BPN (due to 
the comparable affinity of BPN and naloxone for the mu opioid receptor), in practice, polydrug overdoses in 
which BPN is implicated generally respond to routine doses of naloxone (e.g. 1-2mg IM/IV). 
 
The specific potential risks of the depot BPN product are the prolonged plasma levels of BPN, rather than 
higher plasma levels compared to sublingual dosing, hence there may be no greater risk of overdose occurring 
from depot BPN formulations. However the prolonged duration of depot BPN formulations requires patients to 
be clinically monitored for extended periods of time, until the patient has recovered, and may require prolonged 
monitoring and a naloxone infusion in a hospital setting. Note that depot BPN Buvidal® must be administered 
as a subcutaneous injection.  
 
7.2 Polydrug use and regular intoxication 
 
The issue of administering depot BPN doses to an intoxicated patient is addressed in section 5.10.1. Specific 
interventions may be required for patients with harmful patterns of substance use of other drugs, such as 
alcohol, benzodiazepine, stimulants, cannabis and/or injecting drug use. These are described in Drug misuse 
and dependence: UK guidelines on clinical management 6. 
 
Patients with patterns of regular and harmful substance use often benefit from regular clinical monitoring and 
review, which may be more difficult to schedule in patients attending for dosing only once a month. If more 
frequent clinical reviews are required and the patient has a history of non-attendance for scheduled 
appointments, then a medication option with a more frequent dosing interval may be considered. Patients with 
heavy and regular/ dependent patterns of use of alcohol, benzodiazepines and stimulants (and other 
psychoactive substances) may require specific psychosocial interventions aimed at reducing/ceasing use of 
those substances. 
 
7.3 Acute pain management in patients in depot BPN treatment 
 
Patients on opioid agonist treatment can encounter episodes of acute pain that require management, which 
can be complicated by BPN treatment. Nevertheless, there are evidence-based approaches for pain 
management and it is important that patients have access to effective pain management. 
 
BPN has high mu receptor affinity and reduces the effects of most full opioid agonists such as morphine or 
oxycodone. Whilst this has little impact on the management of mild acute pain (where NSAIDs or paracetamol 
and physical therapies may be considered), BPN can complicate routine opioid analgesia in the management 
of severe acute pain (e.g. in acute/emergency situations such as trauma, renal stones). It is important that 
patients’ acute pain is effectively managed and in such circumstances, Drug misuse and dependence: UK 
guidelines on clinical management 6 recommend the following approaches:  
 
• use of higher doses of traditional opioids such as morphine (with careful titration of effects) 
• use of mu opioid receptor super agonists such as fentanyl that themselves have higher mu intrinsic 
activity than BPN; and/or   
• use of non-opioid analgesic approaches such as ketamine infusions or regional analgesia. 
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Similar approaches can be used for patients with depot BPN treatment to achieve analgesia in 
acute/emergency situations. It is not possible to reverse or cease BPN plasma levels in patients treated with 
depot BPN formulations. 
 
7.4 Chronic pain management in patients in depot BPN treatment 
 
Chronic pain is common amongst patients on OST and is often managed or ‘masked’ by the high doses of 
methadone or BPN used to treat opioid dependence. Whilst current evidence does not identify the most 
effective strategies for treating chronic pain in patients in methadone or BPN treatment, general principles of 
chronic pain management should be followed and include patient education and engagement in the treatment 
process, appropriate use of opioid and non-opioid medications (e.g. antidepressants, NSAIDs, paracetamol,), 
physical (e.g. exercise, physiotherapy) and psychosocial (e.g. Cognitive Behavioural Therapy) interventions 6.  
 
BPN itself is a powerful opioid analgesic, and extended-release BPN formulations (e.g. 7-day topical patches) 
have historically been incorporated into treatment plans for patients with concurrent chronic pain, and it is 
possible that depot BPN formulations may also be effective as part of treatment plans in managing comorbid 
chronic pain in dependent opioid users.  There is no evidence currently available evaluating high dose 
sublingual and depot BPN formulations in chronic pain management.  
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8   Use of depot BPN for withdrawal 
treatment 
 
There is considerable interest among patients and clinicians in the use of long-acting depot BPN formulations 
to assist in withdrawal from opioids such as heroin or methadone, given their long duration of action, gradual 
taper of BPN plasma levels, and logistic simplicity (e.g. one single dose without need for daily dosing). The 
gradual taper over days (for weekly Buvidal®) or weeks (monthly Buvidal®) may be well suited to assisting 
patients attempting opioid withdrawal. 
 
However, at this time there is little clinical experience or research evidence to inform the use of depot BPN for 
managing opioid withdrawal, and further research is required. Consultation with a suitable addiction specialist 
prescriber is recommended. 
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9  Special populations and settings 
 
9.1 High risk or vulnerable populations 
 
There are a range of health conditions (e.g. cognitive impairment, severe psychiatric conditions, poor mobility), 
social circumstances (e.g. safeguarding concerns, domestic violence, homelessness, poor literacy, social 
isolation) and demographics (culturally diverse backgrounds, women, LGBTQ+ people, culturally diverse 
communities, prisoners, older people) that can greatly impact upon the experience of engagement of patients 
with opioid treatment (and other service) providers. The introduction of depot BPN treatment allows for dosing 
on a weekly or monthly basis and may enhance patient autonomy in some cases; alternatively it may detract 
from the ability to engage the patient with treatment and other services. Particular attention to informed consent 
to treatment with depot formulations is required, and advocacy services should be available. Service providers 
and patients should collaboratively implement strategies that aim to enhance attendance for dosing and clinical 
reviews and consider active follow-up strategies for patients who do not attend for scheduled appointments. 
This is a particular challenge when shifting from daily dispensing of medication which may be supervised. The 
risk of loss of contact with the patient needs to be weighed up against the risk of missed doses, poor 
compliance with medication or even complete disengagement with the treatment process if SL BPN is not 
considered. 
 
Protection of vulnerable patients who are opioid dependent can result in serious challenge. Patients who are 
being exploited, or are in domestically violent settings, or on witness protection programs often require flexible, 
responsive and rapid treatment approaches to stabilise opioid dependence while often considering a 
geographical move to a place of safety. The option to rapidly induct a patient onto a long-acting preparation 
offers a window of flexibility for other services such as police, social services and housing charities to work to 
remove the patient from danger whilst not disrupting or jeopardising OST. 
 
9.2 Hospital and secure environment settings 
 
Many patients in OST have brief episodes of admission to hospital or secure environment settings (e.g. prison) 
that result in interruptions in methadone or BPN dosing. It is expected that this will be less of a concern with 
depot BPN treatment, nevertheless, in this situation careful co-ordination between hospital and secure 
environment settings will be required.  
 
During acute admission in hospital settings coexisting opioid dependence and associated withdrawal 
symptoms, or drug seeking and taking behaviour can undermine the admission, resulting in patients taking 
their own discharge against  medical advice, or demonstrating behavior that is disruptive and difficult to 
manage in an acute care setting. Attempts to provide rapid stabilisation of opioid dependence are often made 
to support the patient in being able to sustain the admission. Methadone or SL BPN are both options in this 
situation, however depot BPN may provide an alternative with significant advantages due to its weekly and 
monthly administration, and it may also provide a degree of protection against overdose if a patient does leave 
abruptly without securing onward prescribing. Management of acute pain will have to be considered on a case-
by-case basis in respect of the interaction between BPN and full opioid receptor agonists. Benefits of BPN in 
acute care settings include its relatively low risk of respiratory depression and sedation compared with full 
opioid agonists. 
 
Police custody settings also present a unique challenge in managing opioid dependence and withdrawal 
symptoms, and also in ensuring continuity of OST. Often patients are detained for short periods of time, outside 
of usual working hours and with limited access to prescribing services. There are a number of factors which 
influence which, if any, treatments are offered for acute amelioration of acute opioid withdrawal, and whether or 
not the patient will have access to daily supervised doses of OST. 
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Patients who are maintained on depot BPN preparations should present less of a challenge in these settings 
due to weekly or monthly administration with a window of flexibility around dosing days making it relatively 
straight forward to maintain treatment continuity which, in turn, improves patient safety. 
 
9.3 Secure environment settings 
 
Depot BPN has a number of potential benefits as a treatment option in secure environment settings. Diversion 
of SL BPN is commonplace in prisons and is associated with interpersonal violence as well as viral and non-
viral injecting-related injuries and diseases. Within the UK prison estate, insufflation is a common method of 
abusing BPN. Diversion and misuse of SL BPN in the UK HMP estate is endemic, and there is evidence that 
supply and distribution is organised with significant financial implications. Reports of debt, bullying and assault 
are commonplace and have significant costs, both to the individual, their family and also across the secure 
estate.  Depot BPN formulations have less capacity for diversion and compliance is easier to ensure. 
Individuals who receive effective BPN treatment are unlikely to engage in BPN abuse, therefore reducing 
demand for illicit products. 
 
Administration of SL BPN in prisons is time-intensive, with individual patients taking 10-20 minutes for SL 
formulations to dissolve, requiring considerable time resources for both prison officers and health staff. Novel 
lyophilisate preparations do dissolve more rapidly, reducing supervision time, however they do not remove the 
requirement for staff to supervise daily doses. Once-a-month administration of depot BPN will allow increased 
time for patients to receive other health interventions. Depot BPN can also be delivered in secure environment 
healthcare settings, removing the risk of bullying that can result from patients having to disclose their treatment 
to other inmates. 
 
The period immediately following release from custody is a high-risk period for patients, with significant risk of 
overdose and death. It is widely accepted that enforced periods of abstinence from opioids whilst in custodial 
settings results in loss of tolerance and a significant increased risk of fatal overdose if opioid use is reinstated 
on release. Evidence suggests that provision of OST within HMP and on release results in a 75% reduction in 
all-cause mortality and an 85% reduction in mortality from opioid overdose in the first month following release 
24. HMPs have responded to this risk by offering a wide range of OST options within the secure setting that 
should reflect a degree of equivalence with community services, and also by offering re-titration onto OST prior 
to release. However there is variation in provision throughout the secure estate and many challenges to 
providing smooth transition of prescribing on release. Unexpected release from court, or short sentences can 
present challenges including the timely identification of a community prescriber, and issues with complexity of 
social situation can interfere with patients’ engagement with community providers during the transition period. A 
depot preparation may provide greater stability over this period with less urgency for immediate attendance at 
community clinic or pharmacy. This may be beneficial for both the patient and community treatment teams. 
 
Patients on depot BPN leaving custody should be provided education regarding the persistent clinical effects 
and duration of depot BPN. 
 
As depot BPN may take several doses to reach steady state, transfer of care documentation both on entry into 
custody and on release will require detailed documentation of doses given over a period several months. 
 
There is a need for flexibility in transferring between depot BPN and oral OST, in case availability is not 
consistent across settings. It is straightforward to transition between SL and depot BPN, and if needed, patients 
can be transferred from depot to SL BPN when the next depot dose is due, at an equivalent dose. Transferring 
to a full opioid agonist such as methadone will not be as straightforward, due to the extended wash out period 
of depot BPN, and therefore there is potentially reduced effectiveness of methadone for an extended period 
following depot BPN administration.  
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9.4 Residential rehabilitation and supported housing settings 
 
There are a variety of community residential settings that can provide challenges for maintaining patients on 
OST. Supported living projects are becoming increasingly common in the UK. They are often faith-based and 
are not included under the residential rehabilitation frameworks. As housing-based projects they do not require 
registration as care homes and do not have facilities for managing or dispensing controlled drug medications 
on site. Many aspire for patients to be abstinent from prescribed opioids, but this may in part be due to the 
challenges of supporting patients to attend for daily supervised medications, and also due to the problems 
associated with introducing opioid medications such as methadone or SL BPN into their setting. The risk of 
patients living in supported living projects relapsing following either planned or unplanned exit is high, with the 
associated increased risk of overdose due to loss of tolerance. Depot BPN may provide an option for patients 
to be maintained on OST during extended stays in therapeutic communities, removing any requirement for 
medication storage on site and pharmacy attendances. 
 
Most residential rehabilitation units in the UK are abstinence based in their approach, and would usually expect 
patients to be opioid free, or undergo detoxification prior to fully engaging in an inpatient rehabilitation program. 
This does create a barrier for many patients who are not ready for abstinence. Some units will consider an 
integrated approach, allowing patients to remain on OST, and depot BPN may provide an opportunity to have a 
bridge between OST and recovery, further integrating the patient journey through medically assisted recovery. 
 
By moving away from a daily dosing structure of a medication which has significant abuse potential, to a 
preparation which is administered weekly and monthly, and achieves consistently stable plasma levels 
between doses, patients and treatment providers can start to explore the complex relationship between 
chemical dependence and addiction. A more flexible approach for delivering bespoke recovery care options 
could support a holistic and integrated model of medically assisted recovery. 
 
Treatment with depot BPN should be delivered within a framework of comprehensive assessment of the 
patient’s chemical dependence, general health, social functioning, and should be underpinned by regular 
reviews with a keyworker 6.There are specific aspects of depot BPN treatment that will need to be addressed: 
 
• adapting delivery of ongoing support and connection, especially if the patient is moving from very 
regular contact with a service due to removal of daily supervised medication 
• encouraging patients to think about how they will fill their time positively, in a way that helps them move 
forward, become healthier and improve self-esteem 
• making sure patients have access to the patient leaflets for Buvidal®.   
 
Clinicians considering depot BPN treatment should be sensitive to the diversity of patients including: 
 
• being aware that some cultures will have restrictions around the gender of the person who can give 
them an injection. 
• being aware that there may be cultural issues around injecting in particular sites. 
• understanding that using a professional interpreter is always preferable to using a family member, for 
clearer, unbiased and confidential exchange of information. 
 
All in all, the best therapeutic relationships are built on co-operation, unbiased information sharing and an 
honest and open exchange that balances clinical responsibilities with the patient’s treatment goals. 
 
9.5 Managing travel 
 
Patients must not be supplied directly with Buvidal®. Depot BPN must only be handled by a healthcare 
professional prior to administration. BPN must only be handled by a healthcare professional after delivery to a 
clinic/administration site or collection from the community pharmacy by a healthcare professional or practitioner 
from the drug service provider.  
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9.5.1 Local travel 
 
The duration of action of depot BPN should make local travel less problematic for patients. For information on 
doses that need to be given before/after the scheduled date see section 5.6. 
 
9.5.2 Overseas travel 
 
Weekly Buvidal® cannot be given to patients for overseas travel for more than 9 days and for monthly Buvidal® 
if the travel duration is more than five weeks. Patients wishing to travel abroad for longer periods may have to 
be transferred back to SL BPN. Dose titration of the required sublingual dose should occur before travel 
commences so patients can be observed during transfer from depot BPN to SL BPN. 
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10  Patient information and perspective  
 
Depot BPN should always be presented as one choice in the range of available OST medications. Patients 
may need a great deal of information and reassurance from clinicians as they assess whether depot BPN will 
be compatible with their lifestyles and where they are in their treatment journeys. This support will need to 
continue if a patient decides to receive depot BPN treatment. No matter the advantages of the new formulation, 
the depot injection is a leap in the dark that for many patients will signify a relinquishment of control, and also a 
significant change from the routine of daily attendance for dosing. 
 
There will be patients who wish to transition to depot BPN who are currently in treatment on both sublingual 
BPN and also methadone.  All patients will need to know how depot BPN medication is similar to, and different 
from, the formulation they are currently taking, and what is involved in transitioning. 
 
The decision-making process and initiation or transitioning phase should occur within a co-operative 
therapeutic relationship that balances a clinician’s medical expertise and knowledge and with a patient’s 
treatment goals. 
 
Patients need to be supplied with a wide range of information about depot BPN. Patients may want to know 
about: 
 
• product pharmacology profile, effectiveness and safety including half-life and average peak/trough 
patterns, control of cravings  
• prescribing and dosing procedures including dose amounts, duration of effect and dosing schedule 
• the way transfer from other OST medications will take place and if they will experience withdrawal 
symptoms 
• options for managing side effects, chronic and acute pain and exiting the program 
• any other problems that might arise and how they might be addressed 
• their rights and responsibilities. 
. 
As a clinician, patient agency and choice can be enhanced by: 
 
• recognising that depot BPN will suit some but not all people currently in treatment, or considering 
entering treatment and that a choice of a range of OST medications is an essential health response 
• listen to, take seriously and act promptly when patients describe their experience – including subjective 
feelings of opioid withdrawal or cravings to use opioids 
• encouraging patients to compile a list of advantages and disadvantages to help with decision-making 
• offering a move to depot BPN as a trial, reassuring your patient that they will be able to return to 
sublingual BPN or methadone if depot BPN does not suit them 
• respecting a patient’s decision to not try depot BPN, no matter what their reasons are 
• making sure the patient has sufficient harm reduction information if they do not want to be abstinent 
from all illicit drugs, with special attention to overdose risks and reversal. 
 
There are many patients who will find depot BPN fits well with their treatment goals, but because they may 
have less contact with prescribers and/or dosing agencies, they may need support that is different from 
patients on other OST medications.  
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11 Buvidal® and the DVLA  
 
Doctors and other healthcare professionals should:  
 
• advise the patient on the impact of their medical condition for safe driving ability  
• advise the patient on their legal requirement to notify the DVLA of any relevant condition  
• treat, manage and monitor the patient’s condition with ongoing consideration of their fitness to drive  
• Notify the DVLA when fitness to drive requires notification but an individual cannot or will not notify the 
DVLA themselves 
• the DVLA guidance does not make specific reference to depot BPN but outlines the current guidance 
for patients on oral methadone or BPN. Chapter 5 of the DVLA guidance and should be adhered to 
under usual situations 25. 
• the DVLA guidance will require updating in line with the new depot treatment formulations available. In 
the interim, it is advised that prescribers of Buvidal® apply the existing guidance which is to advise 
patients that they must not drive, and that they must notify the DVLA of their medical condition and the 
medication prescribed 
• the SPCs for Buvidal® state that buprenorphine has minor to moderate influence on the ability to drive 
and use machines when administered to opioid-dependent patients. Buprenorphine may cause 
drowsiness, dizziness or impaired thinking, especially during treatment induction and dose adjustment. 
If used together with alcohol or other central nervous system depressants, the effect is likely to be more 
pronounced. The patient should be cautioned not to drive or operate hazardous machinery whilst taking 
this medicine until it is known how the patient is affected by the medicine. An individual 
recommendation should be given by the treating healthcare professional.  
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12  Governance 
 
12.1 Acquisition 
 
Buprenorphine is considered a controlled Class C drug under the 1971 Misuse of Drugs Act 26. As such, it is 
subject to the Misuse of Drugs (Safe Custody) (Amended) Regulations 2007 27 detailing requirements for 
supply and possession in the UK. Buprenorphine sits in schedule 3 of the regulations. It is subject to special 
prescribing and safe custody requirements. 
 
Prescriptions can be written on FP10, for dispensing to a healthcare professional to be administered in service 
or for administration by a suitably qualified community pharmacist where a Patient Specific Directive is in place. 
 
Buvidal® can be ordered by a service direct from a wholesale supplier where the service is in receipt of a Home 
Office license for the purchase of controlled drugs. 
 
12.2 Storage 
 
Buvidal® injections have no special precautions listed for storage in the SPCs except that the product should 
not be refrigerated or frozen.  
 
As a Class C schedule 3 controlled drug, safe custody is required when storing Buvidal®. This applies when 
healthcare professionals are transporting medication from the pharmacy and storing in clinic facilities on a 
temporary basis 28.  
 
12.3 Accountability 
 
There is no legal requirement to keep a Controlled Drug Register for Buvidal®. However, it is good practice to 
keep a log of stock for transparency and audit purposes. 
 
Buvidal® administration should be recorded clearly within the patient records and include: 
 
• name and date of birth of the person having the dose administered  
• date and time of the dose 
• name, formulation and strength of the controlled drug administered 
• dose of the controlled drug administered 
• name and signature or initials of the person who administered the dose 
• name and signature or initials of any witness to administration  
• the Batch Number and expiry date should also be recorded in the entry. 
 
If a prescriber or drug service loses (or has stolen from them) a drug with abuse potential, they must 
immediately notify the Controlled Drugs Accountable Officer. The police should also be notified where theft has 
occurred. 
 
12.4 Authority to prescribe and administer BPN injections 
 
No specific authorisation is required to prescribe Buvidal® in the UK, other than to be a registered medical or 
non-medical prescriber. Healthcare professionals must have the necessary competencies and/or skills to 
prescribe and administer Buvidal®, as reflected in their area of expertise, training, appraisal and revalidation. 
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Appendix 1 Depot BPN studies 
Study reference Product Setting Author 
NCT02672111 
HS-14-499 (Braeburn) 
Buvidal® Community US/EU/AUS Frost et al 2019 
 
Aims: To assess long-term safety of subcutaneous buprenorphine depot (CAM2038) weekly and monthly 
regimens in adult outpatients with opioid use disorder. 
 
Methods: This phase 3, open-label, multicentre, 48-week study (ClinicalTrials.gov NCT02672111) was 
conducted at 26 sites (US, UK, Hungary, Denmark, Sweden, Germany, and Australia). Participants were 
administered CAM2038 weekly (8, 16, 24, or 32mg) or CAM2038 monthly (64, 96, 128, or 160mg) with 
flexible dosing and individualised titration up or down utilising the multiple CAM2038 weekly and monthly 
dosing options. Safety variables, urine toxicology samples, and self-reported illicit opioid use were collected 
at each visit. 162/227 (71.4%) participants were administered a patient satisfaction survey. 
 
Results: Between December 14, 2015, and April 12, 2017, 228 opioid-dependent participants enrolled, and 
227 participants received CAM2038 (37 initiated directly onto CAM2038 and 190 converted from sublingual 
buprenorphine). 167/227 (73.6%) participants completed the treatment period. 143/227 (63.0%) participants 
reported at least 1 treatment emergent adverse event (TEAE), and 60/227 (26.4%) reported a drug-related 
TEAE. 46/227 (20.3%) participants reported injection site reactions, with most (45/46 [97.8%]) reported as 
mild to moderate. 128/227 (56.4%) of the TEAEs were mild or moderate in severity. Five participants (2.2%) 
discontinued study drug due to a TEAE, of which 2 cases (0.9%) were injection site related. No serious AEs 
were attributed to study drug. At end of study, the percentage of the composite outcome comprising illicit 
opioid-negative urine samples and self-reports was 63.0% (17/37) in new-to-treatment participants and 
82.8% (111/190) for participants converted from sublingual buprenorphine. Participants reported high levels 
of satisfaction with CAM2038. 
 
Conclusions: CAM2038 was well-tolerated and demonstrated a systemic safety profile consistent with the 
known profile of sublingual buprenorphine. Weekly and monthly CAM2038 was associated with high 
retention rates and low levels of continued illicit opioid use throughout the study
29
.
 
 
Study reference Product Setting Author 
NCT02611752 
HS-13-478 (Braeburn) 
Buvidal® US Walsh et al 2017 
 
Importance: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral 
transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations 
may be obviated by a sustained release formulation. 
 
Objective: To evaluate the ability of a novel, weekly, subcutaneous buprenorphine depot formulation, 
CAM2038, to block euphorigenic opioid effects and suppress opioid withdrawal in non–treatment-seeking 
individuals with OUD. Design, Setting and Participants: This multisite, double-blind, randomized within-
patient study was conducted at 3 controlled inpatient research facilities. It involved 47 adults with DSM-V 
moderate-to-severe OUD. The study was conducted from October 12, 2015 (first patient enrolled), to April 
21, 2016 (last patient visit). 
 
Interventions: A total of five 3-day test sessions evaluated the response to hydromorphone (0, 6, and 18mg 
intramuscular in random order; 1 dose/session/day). After the first 3-day session (ie, qualification phase), 
participants were randomized to either CAM2038 weekly at 24mg (n = 22) or 32mg (n = 25); the assigned 
CAM2038 dose was given twice, 1 week apart (day 0 and 7). Four sets of sessions were conducted after 
randomization (days 1-3, 4-6, 8-10, and 11-13). Weekly CAM2038 doses were initiated directly from adults 
maintained on oral morphine. 
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Main Outcomes and Measures: The primary end point was maximum rating on the visual analog scale for 
drug liking. Secondary end points included other visual analog scale (eg, high and desire to use), opioid 
withdrawal scales, and physiological and pharmacokinetic outcomes 
 
Results: A total of 46 of 47 randomized participants (mean [SD] age, 35.5 [9] years; 76% male [n = 35]) 
completed the study. Both weekly CAM2038 doses produced immediate and sustained blockade of 
hydromorphone effects (liking maximum effect, CAM2038, 24mg: effect size, 0.813; P < .001, and CAM2038, 
32mg: effect size, 0.753; P < .001) and suppression of withdrawal (Clinical Opiate Withdrawal Scale, 
CAM2038, 24mg: effect size, 0.617; P < .001, and CAM2038, 32mg: effect size, 0.751; P < .001). CAM2038 
produces a rapid initial rise of buprenorphine in plasma with maximum concentration around 24 hours, with 
an apparent half-life of 4 to 5 days and approximately 50% accumulation of trough concentration from first to 
second dose (trough concentration = 0.822 and 1.23 ng/mL for weeks 1 and 2, respectively, with 24mg; 
trough concentration = 0.993 and 1.47 ng/mL for weeks 1 and 2,  respectively, with 32mg). 
 
Conclusions and Relevance: CAM2038 weekly, 24 and 32mg, was safely tolerated and produced immediate 
and sustained opioid blockade and withdrawal suppression without any evidence of precipitating withdrawal 
upon depot initiation. The results support the use of this depot formulation for treatment initiation and 
stabilization of patients with OUD, with the further benefit of obviating the risk for misuse and diversion of 
daily buprenorphine while retaining its therapeutic benefits10. 
 
Study reference Product Setting Author 
EudraCT # 2008-006348-20 
HS-07-307 (Camurus AB) 
Buvidal® Hamburg, Germany Haasen et al 2017 
 
Introduction: Sublingual buprenorphine is effective for opioid dependence treatment but associated with 
misuse, abuse, and diversion. The present Phase I/II study evaluated a novel buprenorphine subcutaneous 
depot formulation for once-weekly dosing (CAM2038 q1w) in patients receiving maintenance treatment for 
opioid use disorder with daily sublingual buprenorphine. 
 
Methods: After discontinuation of buprenorphine for 48 h, patients received a single CAM2038 q1w dose 
based on their pre-study daily sublingual maintenance dose. CAM2038 q1w doses of 7.5, 15, 22.5, and 
30mg were administered in a sequential dose-escalating design. The following assessments were 
performed: pharmacokinetics of buprenorphine and norbuprenorphine, pharmacodynamics (evaluated using 
the Subjective and Clinical Opiate Withdrawal Scales), and time to intake of rescue sublingual buprenorphine 
medication. 
 
Results: Single doses of CAM2038 q1w indicated dose-proportional buprenorphine pharmacokinetics (Cmax 
and AUC0–7d), with time to Cmax ~20 h and an apparent terminal half-life of 3–5 days, supporting once-
weekly dosing. On average, patients showed a rapid and extended decrease in opiate-withdrawal symptoms 
from baseline, with zero or very low SOWS and COWS values measured at least up to 7 days after dosing of 
CAM2038 q1w. The median time to first use of rescue buprenorphine was 10 days. No dose dependence 
was seen in the pharmacodynamics, attributable to the selection of CAM2038 q1w doses based on patients’ 
pre-study maintenance doses. CAM2038 q1w was safe and generally well tolerated. 
 
Study reference Product Setting Author 
HS-11-426 (Camurus AB) 
HS-13-487 (Camurus AB) 
Buvidal® UK Liu et al 2018 
 
CAM2038, FluidCrystal injection depot, is an extended release formulation of buprenorphine given 
subcutaneously every 1 week (Q1W) or every 4 weeks (Q4W). The purpose of this research was to predict 
the magnitude of drug- drug interaction (DDI) after coadministration of a strong CYP3A4 inducer or inhibitor 
using physiologically based pharmacokinetic (PBPK) modelling. 
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A PBPK model was developed for CAM2038 based on the previously published buprenorphine PBPK model 
after intravenous and sublingual administration and the PK profiles after subcutaneous administration of 
CAM2038 from 2 phase I clinical trials. The strong CYP3A4 inhibitor ketoconazole was predicted to increase 
the buprenorphine exposure by 35% for the Q1W formulation and 34% for Q4W formulation, respectively. 
Also, the strong CYP3A4 inducer rifampin was predicted to decrease the buprenorphine exposure by 26% 
for both the Q1W and Q4W formulations. 
 
The results provided insight into the potential DDI effect for CAM2038 and suggested a lack of clinically 
meaningful DDI when CAM2038 is co-administered with CYP3A4 inhibitor or inducer. Therefore, no dose 
adjustment is required when CAM2038 is co-administered with CYP3A4 perpetrators 30. 
 
Conclusions: Pharmacokinetics and pharmacodynamics of a novel buprenorphine subcutaneous depot 
formulation for once-weekly dosing was evaluated, suggesting utility in maintenance treatment of patients 
with opioid use disorder 31. 
 
Study reference Product Setting Author 
NCT02651584 
HS-11-421 (Braeburn 
Buvidal® Community US Lofwall et al 2018 
 
Objective: To determine whether treatment involving novel weekly and monthly subcutaneous (SC) 
buprenorphine depot formulations is non-inferior to a daily sublingual (SL) combination of buprenorphine 
hydrochloride and naloxone hydrochloride in the treatment of opioid use disorder. 
 
Design, Setting and Participants: This outpatient, double-blind, double-dummy randomized clinical trial was 
conducted at 35 sites in the United States from December 29, 2015, through October 19, 2016. Participants 
were treatment-seeking adults with moderate-to-severe opioid use disorder. 
 
Interventions: Randomization to daily SL placebo and weekly (first 12 weeks; phase 1) and monthly (last 12 
weeks; phase 2) SC buprenorphine (SC-BPN group) or to daily SL buprenorphine with naloxone (24 weeks) 
with matched weekly and monthly SC placebo injections (SL-BPN/NX group). 
 
Main Outcomes and Measures: Primary end points tested for non-inferiority were response rate (10% 
margin) and the mean proportion of opioid-negative urine samples for 24 weeks (11% margin). Responder 
status was defined as having no evidence of illicit opioid use for at least 8 of 10 pre-specified points during 
weeks 9 to 24, with 2 of these at week 12 and during month 6 (weeks 21-24). The mean proportion of 
samples with no evidence of illicit opioid use (weeks 4-24) evaluated by a cumulative distribution function 
(CDF) was an a priori secondary outcome with planned superiority testing if the response rate demonstrated 
non-inferiority. 
 
Results: A total of 428 participants (263 men [61.4%] and 165 women [38.6%]; mean [SD] age, 38.4 [11.0] 
years) were randomized to the SL-BPN/NX group (n = 215) or the SC-BPN group (n = 213). The response 
rates were 31 of 215 (14.4%) for the SL-BPN/NX group and 37 of 213 (17.4%) for the SC-BPN group, a 
3.0% difference (95%CI, −4.0% to 9.9%; P < .001). The proportion of opioid-negative urine samples was 
1099 of 3870 (28.4%) for the SL-BPN/NX group and 1347 of 3834 (35.1%) for the SC-BPN group, a 6.7% 
difference (95%CI, −0.1%to 13.6%; P < .001). The CDF for the SC-BPN group (26.7%) was statistically 
superior to the CDF for the SL-BPN/NX group (0; P = .004). Injection site adverse events (none severe) 
occurred in 48 participants (22.3%) in the SL-BPN/NX group and 40 (18.8%) in the SC-BPN group. 
 
Conclusions and Relevance: Compared with SL buprenorphine, depot buprenorphine did not result in an 
inferior likelihood of being a responder or having urine test results negative for opioids and produced superior 
results on the CDF of no illicit opioid use. These data suggest that depot buprenorphine is efficacious and 
may have advantages 10 . 
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Study reference Product Setting Author 
ISRCTN24987553 
HS-13-487 (Camurus AB) 
Buvidal® UK Albayaty et al 2017 
 
Introduction: CAM2038 q1w (once weekly) and q4w (once monthly) are investigational buprenorphine 
subcutaneous (SC) formulations based on FluidCrystal® injection depot technology. These two drug products 
are being developed for opioid dependence treatment, with a target for once-weekly and once-monthly SC 
dosing. The rationale for developing two products with different dosing frequencies is that treatment 
strategies/routines, and hence different treatment preferences, can vary between patients, different stages of 
opioid maintenance treatment, and countries. This study evaluated the pharmacokinetics and safety of 
buprenorphine and norbuprenorphine following administration of CAM2038 q1w or q4w versus active 
controls. 
 
Methods: Healthy volunteers were randomized to five treatment groups. All received a single intravenous 
dose of buprenorphine 600 micrograms, followed post-washout by a single dose of CAM2038 q4w 96mg, a 
single dose of CAM2038 q4w 192mg, or sublingual buprenorphine 8, 16, or 24mg daily for 7 days, followed 
post-washout by a single dose of CAM2038 q4w 64 or 128mg or four repeated weekly doses of CAM2038 
q1w 16mg. All subjects received daily naltrexone. 
 
Results: Eighty-seven subjects were randomized. Median buprenorphine tmax after CAM2038 q4w was 4–
10 h (24 h for CAM2038 q1w); mean terminal half-life was 19–25 days (5 days for CAM2038 q1w). CAM2038 
q4w showed dose-proportional buprenorphine release, with similar exposure to repeat-dose CAM2038 q1w 
at comparable monthly dose level. Both CAM2038 formulations showed complete absolute bioavailability of 
buprenorphine and 5.7- to 7.7-fold greater buprenorphine bioavailability versus sublingual buprenorphine. 
CAM2038 q1w and q4w were well tolerated; subjects’ acceptance was higher for CAM2038 than for 
sublingual buprenorphine 1 h post-dose. 
 
Conclusions: The pharmacokinetic profiles of CAM2038 q1w and q4w versus sublingual buprenorphine 
support expected treatment efficacy with once-weekly and once-monthly dosing, respectively. CAM2038 
formulations were safe and showed good local tolerability 32. 
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Appendix 2 Adverse reactions (from 
Buvidal SPC) 
 
 
Adverse reactions listed by body system 
System Organ Class Very common Common Uncommon Not known 
Infections and 
infestations 
 
Infection 
Influenza 
Pharyngitis 
Rhinitis 
Injection site 
cellulitis 
 
Blood and lymphatic 
system disorders 
 
Lymphadenopathy 
  
Immune system 
disorders 
 
Hypersensitivity 
  
Metabolism and 
nutrition disorders 
 
Decreased appetite 
  
Psychiatric disorders Insomnia Anxiety 
Agitation 
Depression 
Hostility 
Nervousness 
Thinking abnormal 
Paranoia 
Medical dependence 
 
Hallucinations 
Euphoric mood 
Nervous system 
disorders 
Headache Somnolence 
Dizziness 
Migraine 
Paraesthesia 
Syncope 
Tremor 
Hypertonia 
Speech disorders 
  
Eye disorders 
 
Lacrimal disorder 
Mydriasis 
Miosis 
  
Ear and labyrinth 
disorders 
  
Vertigo 
 
Cardiac disorders 
 
Palpitations 
  
Vascular disorders 
 
Vasodilation 
Hypotension 
  
Respiratory, thoracic 
and mediastinal 
disorders 
 
Cough 
Dyspnoea 
Yawning 
Asthma 
Bronchitis 
  
Gastrointestinal 
disorders 
Nausea Constipation 
Vomiting 
Abdominal pain 
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Flatulence 
Dyspepsia 
Dry mouth 
Diarrhoea 
Gastrointestinal 
disorder 
Hepatobiliary 
disorders 
  
Alanine 
aminotransferase 
increased 
Aspartate 
aminotransferase 
increased 
Hepatic enzymes 
increased 
 
Skin and 
subcutaneous tissue 
disorders 
 
Rash 
Pruritus 
Urticaria 
Rash macular Erythema 
Musculoskeletal and 
connective tissue 
disorders 
 
Arthralgia 
Back pain 
Myalgia 
Muscle spasms 
Neck pain 
Bone pain 
  
Renal and urinary 
disorders 
   
Urinary retention 
Reproductive system 
and breast disorders 
 
Dysmenorrhoea 
  
General disorders and 
administration site 
conditions 
Hyperhidrosis 
Drug withdrawal 
syndrome 
Pain 
Injection site pain 
Injection site pruritus 
Injection site erythema 
Injection site swelling 
Injection site reaction 
Injection site 
induration 
Injection site mass 
Oedema peripheral 
Asthenia 
Malaise 
Pyrexia 
Chills 
Neonatal withdrawal 
syndrome 
Chest pain 
Injection site 
inflammation 
Injection site 
bruising 
Injection site 
urticaria 
 
Investigations 
 
Abnormal liver 
function tests 
  
Injury, poisoning and 
procedural 
complications 
  
Procedural 
dizziness 
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Appendix 3 Drug-drug interactions (DDIs) 
 
Drug-drug interactions of potential clinical relevance with depot BPN 
 
No interaction studies have been performed with Buvidal. 
Buprenorphine should be used cautiously when co-administered with: 
• benzodiazepines: This combination may result in death due to respiratory depression of central origin. 
Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a 
risk of misuse. Patients should be warned that it is extremely dangerous to self-administer non-prescribed 
benzodiazepines whilst taking this product, and should also be cautioned to use benzodiazepines concurrently 
with this product only as directed by their physician  
• gabapentinoids: This combination may result in death due to respiratory depression. Therefore, dosages must 
be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients 
should be cautioned to use gabapentinoids (such as pregabalin and gabapentin) concurrently with this product 
only as directed by their physician  
• alcoholic drinks or medicinal products containing alcohol as alcohol increases the sedative effect of 
buprenorphie 
• other central nervous system depressants: Other opioid derivatives (e.g. methadone, analgesics and 
antitussives); certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than 
benzodiazepines, antipsychotics, clonidine and related substances. These combinations increase central 
nervous system depression. The reduced level of alertness can make driving and using machinery hazardous  
• opioid analgesics: Adequate analgesia may be difficult to achieve when administering a full opioid agonist in 
patients receiving buprenorphine. The potential for overdose also exists with a full agonist, especially when 
attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are 
declining  
• naltrexone and nalmefene: These are opioid antagonists that can block the pharmacological effects of 
buprenorphine. For opioid-dependent patients currently receiving buprenorphine treatment, naltrexone may 
precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms. For patients currently 
receiving naltrexone treatment, the intended therapeutic effects of buprenorphine administration may be 
blocked by naltrexone. 
• Buprenorphine is metabolised to norbuprenorphine primarily by CYP3A4. The effects on buprenorphine 
exposure in patients treated with Buvidal have not been studied. Interaction with co-administered inducers or 
inhibitors have been established in studies using transmucosal and transdermal buprenorphine. Buprenorphine 
is also metabolised to buprenorphine-3β-glucuronide by UGT1A1. 
 
• CYP3A4 inhibitors may inhibit the metabolism of buprenorphine resulting in increased Cmax and 
AUC of buprenorphine and norbuprenorphine. Buvidal avoids first-pass effects and CYP3A4 
inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir, or azole antifungals such as 
ketoconazole or itraconazole, or macrolide antibiotics) are expected to have less effects on 
buprenorphine metabolism when co-administered with Buvidal as compared to when co-
administered with sublingual buprenorphine. When switching from sublingual buprenorphine to 
Buvidal, patients may need to be monitored to ensure plasma buprenorphine levels are adequate. 
Patients already on Buvidal who start treatment with CYP3A4 inhibitors should be treated with 
weekly Buvidal and be monitored for signs and symptoms of overtreatment. Conversely, if a patient 
who is concomitantly treated with Buvidal and a CYP3A4 inhibitor stops treatment with the CYP3A4 
inhibitor, the patient should be monitored for symptoms of withdrawal. 
• CYP3A4 inducers may induce the metabolism of buprenorphine resulting in decreased 
buprenorphine levels. Buvidal avoids first-pass effects and CYP3A4 inducers (e.g. phenobarbital, 
carbamazepine, phenytoin or rifampicin) are expected to have less effects on buprenorphine 
metabolism when co-administered with Buvidal as compared to when co-administered with 
sublingual buprenorphine. When switching from sublingual buprenorphine to Buvidal, patients may 
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need to be monitored to ensure plasma buprenorphine levels are adequate. Patients already on 
Buvidal who start treatment with CYP3A4 inducers should be treated with weekly Buvidal and be 
monitored for signs and symptoms of withdrawal. Conversely, if a patient who is concomitantly 
treated with Buvidal and a CYP3A4 inducer stops treatment with the CYP3A4 inducer, the patient 
should be monitored for symptoms of overtreatment. 
• UGT1A1 inhibitors may affect the systemic exposure of buprenorphine. 
• monoamine oxidase inhibitors (MAOI): Possible exacerbation of the opioids effects, based on experience with 
morphine.
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Appendix 4 Special precautions for 
handling 
 
• Administration should be made into the subcutaneous tissue 
• Intravascular, intramuscular and intradermal administration must be avoided. 
 
- Choose the injection site. Injections should be rotated between sites in the buttock, thigh, abdomen, or upper arm (see Figure 
3) with a minimum of 8 weeks before re-injecting a previously used injection site. Injections on the waistline or within 5 cm of the 
navel should be avoided. 
 
Figure 3: 
- Put on gloves and clean the injection site with a circular motion using an alcohol wipe (not provided in the pack). Do not touch 
the cleaned area again before injecting. 
- While holding the safety syringe by the syringe guard body as shown (see Figure 4), carefully pull the needle shield straight off. 
Immediately dispose of the needle shield (never try to recap the needle). A drop of liquid may be seen at the end of the needle. 
This is normal. 
 
Figure 4: 
- Pinch the skin at the injection site between the thumb and finger as shown (see Figure 5). 
- Hold the safety syringe as shown and smoothly insert the needle at an angle of approximately 90° (see Figure 5). Push the 
needle all the way in. 
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Figure 5: 
- While holding the syringe as shown (see Figure 6), slowly depress the plunger until the plunger head latches between the 
syringe guard wings and all the solution is injected. 
 
Figure 6: 
- Gently pull the needle out of the skin. It is recommended that the plunger is kept fully depressed while the needle is carefully 
lifted straight out from the injection site (see Figure 7). 
 
Figure 7: 
- As soon as the needle has been completely removed from the skin, slowly take the thumb off the plunger and allow the syringe 
guard to automatically cover the exposed needle (see Figure 8). There may be a small amount of blood at the injection site, if 
required wipe with a cotton ball or gauze. 
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